<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        13-262-23
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ELONVA 100 mcg Solution For Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CORIFOLLITROPIN ALFA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1436.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="VETTER PHARMA-FERTIGUNG, GMBH &amp; CO. KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            VETTER PHARMA-FERTIGUNG, GMBH & CO. KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            N.V. Organon
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03GA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:5.8pt">Elonva contains the active ingredient corifollitropin alfa and belongs to the group of medicines called gonadotropic hormones. Gonadotropic hormones play an important role in human fertility and reproduction. One of these gonadotropic hormones is follicle-stimulating hormone (FSH), which is needed in women for the growth and development of follicles (small round sacs in your ovaries that contain the eggs).</p><p>&nbsp;</p><p>Elonva is used to help achieve pregnancy in women having infertility treatment, such as in vitro fertilisation (IVF). IVF involves collecting the eggs from the ovary, fertilising them in the laboratory, and transferring the embryos into the uterus a few days later. Elonva causes the growth and development of several follicles at the same time by a controlled stimulation of the ovaries</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not use Elonva if you:</p><p style="margin-left:34.2pt; margin-right:46.85pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->are allergic (hypersensitive) to corifollitropin alfa or any of the other ingredients of this medicine (listed in section 6)</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have cancer of the ovary, breast, uterus, or brain (pituitary gland or hypothalamus)</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have recently had unexpected vaginal bleeding, other than menstrual, without a diagnosed cause</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have ovaries that do not work because of a condition called primary ovarian failure</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have ovarian cysts or enlarged ovaries</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have polycystic ovarian syndrome (PCOS)</p><p style="margin-left:34.2pt; margin-right:13.95pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have had ovarian hyperstimulation syndrome (OHSS). OHSS is a serious medical problem that can happen when the ovaries are overly stimulated. See below for further explanation.</p><p style="margin-left:34.2pt; margin-right:5.8pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have previously had a treatment cycle of controlled stimulation of the ovaries that resulted in the growth of more than 30 follicles with a size of 11 mm or larger</p><p style="margin-left:34.2pt; margin-right:25.15pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have a basal antral follicle count (the number of small follicles present in your ovaries at the beginning of a menstrual cycle) higher than 20</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have malformations of the sexual organs which make a normal pregnancy impossible</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have fibroid tumours in the uterus which make a normal pregnancy impossible</p><p>&nbsp;</p><p>Warnings and precautions</p><p style="margin-left:5.9pt; margin-right:242.75pt">Talk to your doctor before using Elonva. <u>Ovarian hyperstimulation syndrome (OHSS)</u></p><p>Treatment with gonadotropic hormones like Elonva may cause ovarian hyperstimulation syndrome</p><p style="margin-right:6.25pt">(OHSS). This is a serious medical condition where the ovaries are overly stimulated and the growing follicles become larger than normal. In rare cases, severe OHSS may be life-threatening. Therefore, close supervision by your doctor is very important. To check the effects of treatment, your doctor will do ultrasound scans of your ovaries. Your doctor may also check blood hormone levels. (See also section 4.)</p><p>&nbsp;</p><p style="margin-right:6.25pt">OHSS causes fluid to build up suddenly in your stomach and chest areas and can cause blood clots to form. Call your doctor right away if you have:</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe abdominal swelling and pain in the stomach area (abdomen)</p><p style="margin-left:32.9pt; margin-right:0in; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->feeling sick (nausea)</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->vomiting</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden weight gain due to fluid build up</p><p style="margin-left:32.9pt; margin-right:0in; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->diarrhoea</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->decreased urine output</p><p style="margin-left:32.9pt; margin-right:0in; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->trouble breathing</p><p>&nbsp;</p><p style="margin-right:6.25pt">You may use Elonva only once during the same treatment cycle, otherwise, the chance of having OHSS may increase.</p><p>&nbsp;</p><p style="margin-right:8.4pt">Before starting to use this medicine, tell your doctor if you have ever had ovarian hyperstimulation syndrome (OHSS).</p><p>&nbsp;</p><p><u>Ovarian torsion</u></p><p style="margin-right:6.25pt">Ovarian torsion is the twisting of an ovary. Twisting of the ovary could cause the blood flow to the ovary to be cut off.</p><p>&nbsp;</p><p>Before starting to use this medicine, tell your doctor if you:</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have ever had ovarian hyperstimulation syndrome OHSS.</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->are pregnant or think that you may be pregnant.</p><p style="margin-left:32.9pt; margin-right:0in; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have ever had stomach (abdominal) surgery.</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have ever had a twisting of an ovary.</p><p style="margin-left:32.9pt; margin-right:0in; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have past or current cysts in your ovary or ovaries.</p><p>&nbsp;</p><p><u>Blood clot (Thrombosis)</u></p><p style="margin-left:5.9pt; margin-right:8.4pt">Treatment with gonadotropic hormones like Elonva may (just as pregnancy) increase the risk of having a blood clot (thrombosis). Thrombosis is the formation of a blood clot in a blood vessel.</p><p>&nbsp;</p><p>Blood clots can cause serious medical conditions, such as:</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->blockage in your lungs (pulmonary embolus)</p><p style="margin-left:32.9pt; margin-right:0in; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->stroke</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->heart attack</p><p style="margin-left:32.9pt; margin-right:0in; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->blood vessel problems (thrombophlebitis)</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->a lack of blood flow (deep venous thrombosis) that may result in a loss of your arm or leg.</p><p>&nbsp;</p><p>Please discuss this with your doctor, before starting treatment, especially if:</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you know you already have an increased chance of having a thrombosis</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you, or anyone in your immediate family, have ever had a thrombosis</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you are severely overweight.</p><p>&nbsp;</p><p><u>Multiple births or birth defects</u></p><p style="margin-left:5.9pt; margin-right:12.05pt">There is an increased chance of having twins or even more than two babies, even when only one embryo is transferred into theuterus. Multiple pregnancies carry an increased health risk for both the mother and her babies. Multiple pregnancies and specific characteristics of couples with fertility problems (e.g., a woman&rsquo;s age, certain sperm problems, genetic background of both parents) may also be associated with an increased chance of birth defects.</p><p>&nbsp;</p><p><u>Pregnancy complications</u></p><p style="margin-left:5.9pt; margin-right:12.05pt">If treatment with Elonva results in pregnancy, there is a higher chance of pregnancy outside the uterus (an ectopic pregnancy). Therefore, your doctor should perform an early ultrasound examination to exclude the possibility of pregnancy outside the uterus.</p><p>&nbsp;</p><p><u>Ovarian and other reproductive system tumours</u></p><p style="margin-left:5.9pt; margin-right:12.05pt">There have been reports of ovarian and other reproductive system tumours in women who have had infertility treatment. It is not known if treatment with fertility medicines increases the risk of these tumours in infertile women.</p><p>&nbsp;</p><p><u>Other medical conditions</u></p><p>In addition, before starting to use this medicine, tell your doctor if you:</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have kidney disease.</p><p style="margin-left:32.9pt; margin-right:0in; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have uncontrolled pituitary gland or hypothalamic problems.</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have an underactive thyroid gland (hypothyroidism).</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have adrenal glands that are not working properly (adrenocortical insufficiency).</p><p style="margin-left:32.9pt; margin-right:0in; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have high prolactin levels in the blood (hyperprolactinemia).</p><p style="margin-left:32.9pt; margin-right:12.8pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have any other medical conditions (for example, diabetes, heart disease, or any other long-term disease).</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have been told by a doctor that pregnancy would be dangerous for you.</p><p>&nbsp;</p><p>Other medicines and Elonva</p><p style="margin-right:12.8pt">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p style="margin-right:12.8pt">If you do a pregnancy test during your infertility treatment with Elonva, the test might wrongly suggest that you are pregnant. Your doctor will advise you at what time you can start performing pregnancy tests. In case of a positive pregnancy test, contact your doctor.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p style="margin-right:12.8pt">You should not use Elonva if you are already pregnant, or think that you might be pregnant, or if you are breast-feeding.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Elonva may cause dizziness. If you feel dizzy, you should not drive or use machines.</p><p>&nbsp;</p><p>Elonva contains sodium</p><p style="margin-right:39.75pt">This medicinal product contains less than 1 mmol sodium (23 mg) per injection, i.e. essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:12.8pt">Always use Elonva exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Elonva is used in women having infertility treatment like in vitro fertilisation (IVF). During this treatment, Elonva is used in combination with a medicine (so called GnRH-antagonist) to prevent your</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:5.3pt">ovary from releasing an egg too early. Treatment with the GnRH-antagonist usually starts 5 to 6 days after the injection of Elonva.</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:5.3pt">The use of Elonva in combination with a GnRH agonist (another medicine to prevent your ovary from releasing an egg too early) is not recommended.</p><p>&nbsp;</p><p>Dose</p><p style="margin-left:10.9pt">In the treatment of women of reproductive age, the dose of Elonva is based on weight and age.</p><p>&nbsp;</p><p style="margin-left:39.2pt; margin-right:41.0pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->A single 100-microgram dose is recommended in women who weigh less than or equal to 60 kilograms and who are 36 years of age or younger.</p><p>&nbsp;</p><p style="margin-left:39.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->A single 150-microgram dose is recommended in women:</p><p style="margin-left:67.55pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->who weigh more than 60 kilograms, regardless of age.</p><p style="margin-left:67.55pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->who weigh 50 kilograms or more and who are older than 36 years of age.</p><p>&nbsp;</p><p style="margin-left:10.9pt">Women older than 36 years of age who weighed less than 50 kilograms were not studied.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:13.1pt; vertical-align:top; width:171.6pt" rowspan="2" colspan="2"><p>&nbsp;</p></td><td style="border-color:black; height:13.1pt; vertical-align:top; width:292.7pt" colspan="3"><p style="margin-left:.05pt; text-align:center">Body Weight</p></td></tr><tr><td style="height:13.2pt; vertical-align:top; width:105.0pt"><p style="margin-left:17.45pt">Less than 50 kg</p></td><td style="border-color:black; height:13.2pt; vertical-align:top; width:91.9pt"><p style="margin-left:22.1pt">50 &ndash; 60 kg</p></td><td style="border-color:black; height:13.2pt; vertical-align:top; width:95.75pt"><p style="margin-left:10.95pt">More than 60 kg</p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:74.75pt" rowspan="2"><p>&nbsp;</p><p style="margin-left:5.1pt">Age</p></td><td style="height:25.8pt; vertical-align:top; width:96.85pt"><p style="margin-left:30.05pt; margin-right:23.6pt; text-indent:-6.5pt">36 years or younger</p></td><td style="height:25.8pt; vertical-align:top; width:105.0pt"><p style="margin-left:16.25pt">100 micrograms</p></td><td style="height:25.8pt; vertical-align:top; width:91.9pt"><p style="margin-left:9.65pt">100 micrograms</p></td><td style="height:25.8pt; vertical-align:top; width:95.75pt"><p style="margin-left:11.7pt">150 micrograms</p></td></tr><tr><td style="height:25.8pt; vertical-align:top; width:96.85pt"><p style="margin-left:36.55pt; margin-right:17.7pt; text-indent:-18.75pt">Older than 36 years</p></td><td style="height:25.8pt; vertical-align:top; width:105.0pt"><p style="margin-left:25.25pt">Not studied.</p></td><td style="height:25.8pt; vertical-align:top; width:91.9pt"><p style="margin-left:9.65pt">150 micrograms</p></td><td style="height:25.8pt; vertical-align:top; width:95.75pt"><p style="margin-left:11.7pt">150 micrograms</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:10.0pt">During the first seven days after the injection with Elonva, you should not use (recombinant) Follicle Stimulating Hormone ((rec)FSH). Seven days after the injection of Elonva, your doctor may decide to continue your stimulation cycle with another gonadotropic hormone, like (rec)FSH. This may be continued for a few days until enough follicles of adequate size are present. This can be checked by ultrasound examination. Treatment with (rec)FSH is then stopped and the eggs are matured by giving hCG (human Chorionic Gonadotropin). The eggs are collected from the ovary 34-36 hours later.</p><p>&nbsp;</p><p>How Elonva is given</p><p style="margin-left:10.9pt; margin-right:14.8pt">Treatment with Elonva should be supervised by a physician experienced in the treatment of fertility problems. Elonva must be injected under the skin (subcutaneously) into a skin fold (that you pinch between your thumb and index finger), preferably just below the navel. The injection may be given by a healthcare professional (for example a nurse), your partner or yourself, if carefully instructed by your doctor<em>.</em><em> </em>Always use Elonva exactly as your doctor has told you. You should check with your doctor&nbsp;&nbsp; &nbsp;or pharmacist if you are unsure. A step-by-step &ldquo;instructions for use&rdquo; is given at the end of this leaflet.</p><p>&nbsp;</p><p style="margin-left:10.9pt">Do not inject Elonva into a muscle.</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:10.0pt">Elonva is supplied in pre-filled syringes that have an automatic safety system to help prevent needle stick injuries after use.</p><p>&nbsp;</p><p>If you use more Elonva or (rec)FSH than you should</p><p style="margin-left:10.9pt; margin-right:41.0pt">If you think you have used more Elonva or (rec)FSH than you should, contact your doctor immediately.</p><p>&nbsp;</p><p>If you forget to use Elonva</p><p style="margin-left:10.9pt; margin-right:10.0pt">If you forgot to inject Elonva on the day you should have, contact your doctor immediately. Do not inject Elonva without talking with your doctor.</p><p>&nbsp;</p><p style="margin-left:10.9pt">If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Serious side effects</p><p><strong>&nbsp;</strong></p><p style="margin-right:5.75pt">A possible complication of treatment with gonadotropic hormones like Elonva is unwanted overstimulation of the ovaries. The chance of having this complication can be reduced by carefully monitoring the number of maturing follicles. Your doctor will do ultrasound scans of your ovaries to carefully monitor the number of maturing follicles. Your doctor may also check blood hormone levels. The first symptoms of ovarian overstimulation may be noticed as pain in the stomach (abdomen), feeling sick or diarrhoea. Ovarian overstimulation may develop into a medical condition called ovarian hyperstimulation syndrome (OHSS), which can be a serious medical problem. In more severe cases this may lead to enlargement of the ovaries, collection of fluid in the abdomen and/or chest (which</p><p>may cause sudden weight gain due to fluid buildup) or clots in the blood vessels.</p><p style="margin-left:5.9pt; margin-right:32.75pt; text-align:justify">Contact your doctor without delay if you have pain in the stomach (abdomen) or any of the other symptoms of ovarian hyperstimulation, even if they occur some days after the injection has been given.</p><p>&nbsp;</p><p>The chance of having a side effect is described by the following categories:</p><p>&nbsp;</p><p>Common (may affect up to 1 in 10 women)</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Ovarian hyperstimulation syndrome (OHSS)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Pelvic pain</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Feeling sick (nausea)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Headache</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Pelvic discomfort</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Breast tenderness</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Tiredness (fatigue)</p><p>&nbsp;</p><p>Uncommon ( may affect up to 1 in 100 women)</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Twisting of an ovary (ovarian torsion)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Liver enzyme increases</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Miscarriage</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Pain after oocyte retrieval</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Procedural pain</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Releasing an egg too early (premature ovulation)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Abdominal distension</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Vomiting</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Diarrhoea</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Constipation</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Back pain</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Breast pain</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Bruising or pain at the injection site</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Irritability</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Mood swings</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Dizziness</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Hot flush</p><p>&nbsp;</p><p>Not known (cannot be estimated from available data)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions (hypersensitivity reactions, both local and generalised, including rash).</p><p>&nbsp;</p><p style="margin-right:5.75pt">Pregnancy outside the uterus (an ectopic pregnancy) and multiple pregnancies have also been reported. These side effects are not considered to be related to the use of Elonva, but to Assisted Reproductive Technology (ART) or subsequent pregnancy.</p><p>&nbsp;</p><p>In rare instances, blood clots (thrombosis) that formed inside a blood vessel, broke off, and traveled</p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:12.05pt">inside the bloodstream to block another blood vessel (thromboembolism) have been associated with Elonva therapy as with other gonadotropins.</p><p>&nbsp;</p><p>Reporting of side effects</p><p style="margin-right:12.05pt">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via &ldquo;The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA&rdquo; By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and outer carton after &ldquo;EXP&rdquo; (expiry date). The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Storage by the pharmacist</p><p>Store in a refrigerator (2&ordm;C-8&deg;C). Do not freeze.</p><p>&nbsp;</p><p>Storage by the patient</p><p>There are two options:</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Store in a refrigerator (2&ordm;C-8&deg;C). Do not freeze.</p><p style="margin-left:34.2pt; margin-right:12.8pt; text-indent:-28.3pt"><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Store at or below 30&ordm;C for a period of not more than one month. Make a note of when you start storing the product out of the refrigerator, and use it within one month of that date.</p><p>&nbsp;</p><p>Keep the syringe in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Do not use Elonva</p><p style="margin-left:32.9pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if it has been stored out of the refrigerator for more than one month.</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if it has been stored out of the refrigerator at a temperature of more than 30&ordm;C.</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you notice that the solution is not clear.</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you notice that the syringe or the needle is damaged.</p><p>&nbsp;</p><p style="margin-right:12.8pt">Do not throw away an empty or unused syringe via household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Elonva contains</p><p style="margin-left:32.9pt; margin-right:14.65pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The active substance is corifollitropin alfa.</p><p style="margin-left:32.9pt; margin-right:14.65pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Each Elonva 100 micrograms solution for injection pre-filled syringe contains 100 micrograms in 0.5 millilitre (mL) solution for injection.</p><p style="margin-left:32.9pt; margin-right:14.65pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Each Elonva 150 micrograms solution for injection pre-filled syringe contains 150 micrograms in 0.5 millilitre (mL) solution for injection.</p><p style="margin-left:32.9pt; margin-right:22.8pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The other ingredients are: Sodium citrate dihydrate (3.68 mg), Sucrose (35 mg), Polysorbate 20 (0.10 mg), L-Methionine (0.25 mg), Sodium hydroxide (for pH adjustment) (q.s. to pH 7), Hydrochloric acid (for pH adjustment) (q.s. to pH 7), Water for injections (q.s. to 0.50 ml)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Elonva looks like and contents of the pack
Elonva is a clear and colourless aqueous solution for injection (injection) in a pre-filled syringe with an automatic safety system, which prevents needle stick injuries after use. The syringe is packed together with a sterile injection needle. Each syringe contains 0.5 mL solution.
One pre-filled syringe is available in a single pack.

Elonva is available in two strengths: 100 micrograms and 150 micrograms solution for injection.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder</p><p>Merck Sharp &amp; Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom.</p><p>&nbsp;</p><p>Manufacturer</p><p>Vetter Pharma- Fertigung GmbH &amp; Co. KG, Sch&uuml;tzenstrasse 87 and 99-101, 88212 Ravensburg, Germany</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in Nov 2017.
Version No. (02)

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="text-align:justify" dir="RTL">يحتوي إيلونفا على المادة الفعالة كوريفوليتروبين ألفا وينتمي إلى مجموعة الهرمونات موجهة للغدد التناسلية التي تلعب دورًا مُهمًّا في الإنجاب والخصوبة. أحد هذه الهرمونات الموجهة للغدد التناسلية هو الهرمون المنبه للجريب (FSH) و المهمة للإناث، يُعتبَر هذا الهرمون ضروريًّا لنمو الجُرَيبات في المبيض، التي تتخّذ شكل أكياس مستديرة وصغيرة، تحتوي على البويضات.</p><p style="text-align:justify" dir="RTL">يتمّ استخدام إيلونفا من أجل حدوث الحمل لدى النساء اللواتي يخضعن لعلاج عقم من خلال التلقيح الاصطناعي (IVF) الذي يقضي بجمع البُوَيْضات من المبيض، وتخصيبها في المختبر، ونقل الأجنّة إلى الرحم بعد بضعة أيّام. يؤدي إيلونفا إلى نموّ جريبات عدّة في الوقت نفسه من خلال تحفيز مُراقَب للمبيضَيْن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify" dir="RTL"><strong>لا </strong><strong>تتناولي </strong><strong>إيلونفا في الحالات التالية:</strong></p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- إذا كنتِ مصابة بالحساسيّة من مادة كوريفوليتروبين ألفا أو من أي مكونات أخرى في هذا الدواء (إنظري للبند رقم 6).</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- إذا كان لديك سرطان في المبيض، أو الثدي، أو الرحم، أو الدماغ (الغدة النُخاميّة)</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- إذا أُصِبتِ مؤخّرًا بنزيف مهبلي غير متوقَّع، غير نزيف العادة الشهريّة، بلا سبب معروف</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- إذا كنتِ مصابة بفشل عمل المبيض بسبب حالة تُعرَف بفشل المبيض الأساسي</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- إذا كنتِ مصابة بتكيس المبيض إنتفاخ في المبيض</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- إذا كنتِ مصابة بمتلازمة المبيض متعدّد الأكياس</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- إذا كنتِ مصابة بمتلازمة فرط تحفيز المبيض. تُشكّل هذه المتلازمة مشكلة طبيّة خطرة تحدث عندما يتمّ تحفيز المبيضَيْن بشكل مفرط. إنظري أدناه للحصول على شرح إضافي</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- إذا خضعتِ لعلاج بهدفٍ تحفيزي للمبيضَيْن تحت المراقبة والذي أدّى إلى نمو أكثر من ٣٠ جُرَيْبة حجمها ١١ ملم أو أكثر</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- إذا كان عدد الجُرَيْبات الأساسي (عدد الجريبات الصغيرة الموجودة في المبيضَيْن عند بدء العادة الشهريّة) أكثر من ٢٠</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- إذا كان لديك تشوّهات في الأعضاء التناسليّة، ما يجعل الحمل الطبيعي مستحيلاً</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- إذا كان لديك أورام ليفيّة في الرحم، ما يجعل الحمل الطبيعي مستحيلاً</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>المخاطر و الاحتياطات </strong></p><p style="text-align:justify" dir="RTL">تحدّثي إلى الطبيب قبل استخدام إيلونفا.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>متلازمة فرط تحفيز المبيضَيْن</strong></p><p style="text-align:justify" dir="RTL">قد يُسبّب العلاج بواسطة الهرمونات موجهة للغدد التناسلية، مثل إيلونفا، متلازمة فرط تحفيز المبيض. هي حالة طبيّة خطيرة حيث يتمّ تحفيز المبيضَيْن بشكل مفرط، فتصبح الجُرَيْبات المتنامية أكبر من حجمها العادي. وفي حالات نادرة، قد تهدّد حالة حادة من متلازمة فرط تحفيز المبيض الحياة. وبالتالي، لا بدّ من إشراف الطبيب عليك عن كثب. لمراجعة تأثيرات العلاج، يُجري طبيبُك صورة الموجات فوق الصوتية للمبيضَيْن. كما قد يتأكّد من مستوى الهرمونات في جسمك. (إنظري للبند رقم ٤).</p><p style="text-align:justify" dir="RTL">كما تُسبّب متلازمة فرط تحفيز المبيضَيْن تكدّس السوائل فجأة في معدتك وصدرك وقد تُسبّب تشكّل تخثّرات دمويّة. يجب الاتصال بطبيبك على الفور في حال تعرّضك للحالات التالية:</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- انتفاخ معدي حاد وألم في منطقة المعدة (البطن)</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- الشعور بالغثيان</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- التقيّؤ</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- زيادة الوزن بشكل مفاجئ بسبب تكدّس السوائل</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- الإسهال</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- انخفاض كمية &nbsp;البول</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- صعوبة في التنفّس</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">يمكنكِ إستخدام إيلونفا مرة واحدة خلال دورة العلاج نفسها. وإلاّ، قد تزداد نسبة خطر التعرّض لفرط تحفيز المبيضَيْن.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">قبل البدء باستخدام هذا الدواء، أخبري طبيبك إذا ما تعرّضت في السابق لمتلازمة فرط تحفيز المبيضَيْن.</p><p style="text-align:justify" dir="RTL"><em>&nbsp;</em></p><p style="text-align:justify" dir="RTL"><strong>الالتواء المبيضي</strong></p><p style="text-align:justify" dir="RTL">هو التواء في المبيضَيْن، ممّا قد يوقف التدفّق الدموي إلى المبيض.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">قبل البدء باستخدام هذا الدواء، اخبري طبيبك:</p><p style="text-align:justify" dir="RTL">- إذا ما تعرّضت في السابق لمتلازمة فرط تحفيز المبيضَيْن.</p><p style="text-align:justify" dir="RTL">- إذا كنتِ حاملًا أو تظنّين أنك قد تكونين حاملًا.</p><p style="text-align:justify" dir="RTL">- إذا خضعت في السابق لعمليّة جراحيّة في المعدة (البطن)</p><p style="text-align:justify" dir="RTL">- إذا تعرّضت في السابق لالتواء مبيضي</p><p style="text-align:justify" dir="RTL">- إذا كان لديك، في الماضي أو في الحاضر، تكيسات في أحد المبيضَيْن أو في كلاهما.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>تجلط الدم (الجلطة)</strong></p><p style="text-align:justify" dir="RTL">قد يزيد العلاج بواسطة الهرمونات الموجهة للغدد التناسلية، مثل إيلونفا، (مثل ما يحدث في الحمل) خطر التعرّض لتخثّر دموي، أي تكوين خثرة دمويّة في وعاء دموي.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">يُمكن لتخثّر الدم أن يُسبّب حالات طبيّة خطرة، مثل:</p><p style="text-align:justify" dir="RTL">- انسداد في الرئتين (صمة رئويّة)</p><p style="text-align:justify" dir="RTL">- سكتة</p><p style="text-align:justify" dir="RTL">- نوبة قلبيّة</p><p style="text-align:justify" dir="RTL">- مشاكل في الأوعية الدمويّة (التهاب الوريد الخثاري)</p><p style="text-align:justify" dir="RTL">- نقص في تدفّق الدم (تخثّر وعائي عميق) قد يُؤدّي إلى فقدان ذراع أو رجل</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">يُرجى مناقشة ما يلي مع الطبيب، قبل بدء العلاج، لا سيّما في الحالات التالية:</p><p style="text-align:justify" dir="RTL">- على إطلاع&nbsp; بأن لديك إحتمالية عالية للإصابة بتخثّرالدم</p><p style="text-align:justify" dir="RTL">- تعرّضتِ في السابق أو أي من من أفراد أسرتك لتخثّرالدم</p><p style="text-align:justify" dir="RTL">- تُعانين من الوزن الزائد بشكل حاد</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>تعدّد الولادات أو التشوّهات الخلقيّة</strong></p><p style="text-align:justify" dir="RTL">تزداد فرصة الحمل بتوأم أو حتى أكثر، حتى عند نقل جنين واحد إلى الرحم. قد تُشكّل حالات الحمل المتعدّد خطرًا صحيًّا أكبر بالنسبة إلى الأم وأطفالها. كما قد تُربط حالات الحمل المتعدّد والمواصفات المُحدّدة لأزواج يواجهون مشاكل خصوبة (مثلاً، سنّ المرأة، وبعض مشاكل السائل المنوي، والخلفيّة الوراثيّة للوالدَيْن) بنسبة خطر أعلى بالإصابة بتشوّهات خلقيّة.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>مضاعفات الحمل</strong></p><p style="text-align:justify" dir="RTL">في حال أدّى العلاج بواسطة إيلونفا إلى حمل، ثمة خطر أكبر للحمل خارج الرحم (حمل منتبِذ). لذا، على الطبيب إجراء فحص الموجات فوق الصوتية &nbsp;في وقت مبكر لاستثناء احتمال الحمل خارج الرحم.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>الأورام في المبيضَيْن وأورام أخرى في الجهاز التناسلي</strong></p><p style="text-align:justify" dir="RTL">تُشير تقارير إلى وجود أورام في المبيضَيْن وأورام أخرى في الجهاز التناسلي لدى النساء اللواتي خضعن لعلاج ضدّ العقم. من غير المعروف إذا كان العلاج بواسطة أدوية الخصوبة قد يزيد من خطر الإصابة بهذه الأورام بالنسبة إلى النساء الغير قادرات على الإنجاب.</p><p style="text-align:center" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>الحالات الطبيّة الأخرى</strong></p><p style="text-align:justify" dir="RTL">إضافة إلى ذلك، قبل البدء باستخدام هذا الدواء، اخبري الطبيب على ما يلي:</p><p style="text-align:justify" dir="RTL">- إذا كنتِ مصابةً بمرض في الكُلى</p><p style="text-align:justify" dir="RTL">- إذا كان لديكِ مشاكل في الغدة النُخاميّة</p><p style="text-align:justify" dir="RTL">- إذا كان لديك قصور في الغدّة الدرقيّة</p><p style="text-align:justify" dir="RTL">- إذا كانت الغدد الكظريّة لا تعمل بشكل جيّد (قصور قشرة الكُظَر)</p><p style="text-align:justify" dir="RTL">- إذا كان مستوى البرولكتين مرتفعًا في الدم (فرط البرولكتين في الدم)</p><p style="text-align:justify" dir="RTL">- إذا كان لديك أي حالات طبيّة أخرى (مثلًا، السكري، أو مرض في القلب، أو أي مرض آخر طويل الأمد)</p><p style="text-align:justify" dir="RTL">- إذا قال لك طبيب إن الحمل يُشكّل خطرًا عليك</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>استخدام أدوية أخرى مع إيلونفا</strong></p><p style="text-align:justify" dir="RTL">يُرجى اخبار الطبيب أو الصيدلي في حال كنت تتناولين أدوية أخرى أو أي أدوية قد تناولت منها مؤخّرًا أو قد تتناولين منه لاحقا، بما في ذلك الأدوية التي تُعطى من دون وصفة طبيّة.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL">إذا خضعت لاختبار فحص &nbsp;الحمل خلال فترة علاج العقم بإستخدام إيلونفا ، قد تكون بالخطأ نتيجة &nbsp;الاختبار إيجابي و &nbsp;توحي&nbsp; بوجود حمل. و سيبلغك الطبيب في أي وقت يمكنك البدء في إجراء اختبارات الحمل. اتصلي بطبيبك في حالة اختبار الحمل إيجابية.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>الحمل والرضاعة</strong></p><p style="text-align:justify" dir="RTL">يجب عدم استخدام إيلونفا إذا كنتِ حاملًا أو تشكّين في أنّك قد تكونين حاملًا أو إذا كنت مُرضعًا.</p><p style="text-align:right">أُطلبي المشورة من الطبيب أو الصيدلي قبل تناول هذا الدواء.</p><p style="text-align:right">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p style="text-align:justify" dir="RTL">قد يُسبب إيلونفا الدوران. في هذه الحالة، توقّفي عن القيادة أو عن استخدام الآلات.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>يحتوي إيلونفا على الصوديوم</strong></p><p style="text-align:justify" dir="RTL">يحتوي هذا الدواء على أقل من ١ ملي مول من الصوديوم (٢٣ ملغم) في الحقنة الواحدة، أي شبه &quot;خال من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify" dir="RTL">استخدمي إيلونفا بحسب توجيهات الطبيب تمامًا. عليكِ التأكّد من الطبيب أو الصيدلي في حال لم تكوني متأكّدةً.</p><p style="text-align:justify" dir="RTL">يتمّ إستخدام إيلونفا بالنسبة إلى المرأة التي تخضع لعلاج خصوبة، مثل التلقيح في أنبوب. خلال العلاج، يتمّ استخدام إيلونفا مع دواء آخر (يُعرَف بـمضاد الهرمون المحرّر للغونادوتروفين) من أجل منع المبيض من تحرير بويضة في وقت مبكر جدًّا. يبدأ العلاج عادةً بواسطة هذا المضاد بعد ٥ إلى ٦ أيّام من حقن إيلونفا.</p><p style="text-align:justify" dir="RTL">لا يُوصى باستخدام إيلونفا مع ناهض هرمون محرّر للغونادوتروفين (دواء آخر لمنع المبيض من تحرير بويضة في وقت مبكر جدًّا).</p><p style="text-align:justify" dir="RTL"><strong>&nbsp;</strong></p><p style="text-align:justify" dir="RTL"><strong>الجرعة</strong></p><p style="text-align:justify" dir="RTL">عند معالجة النساء في سنّ الإنجاب، تعتمد جرعة إيلونفا على الوزن والعمر.</p><p style="text-align:justify" dir="RTL">يوصى بجرعة واحدة من ١٠٠ ميكروغرام للمرأة التي وزنها يُساوي أو دون 60 كلغم وعمرها 36 عامًا أو أقل.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">يوصى بجرعة واحدة من ١٥٠ ميكروغرام للمرأة:</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التي وزنها يتجاوز 60 كلغم، بغض النظر عن عمرها.</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التي وزنها يبلغ 50 كلغم أو أكثر وعمرها يتجاوز 36 عامًا.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">المرأة التي يتجاوز عمرها 36 عامًا ووزنها دون 50 كلغم غير مشمولة في الدراسة</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">&nbsp;</p><table style="width:619px" dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:21.65pt; vertical-align:top; width:153.4pt" rowspan="2" colspan="2"><p style="text-align:justify" dir="RTL">&nbsp;</p></td><td style="border-color:black; height:21.65pt; vertical-align:top; width:310.9pt" colspan="3"><p style="text-align:center" dir="RTL"><strong>وزن الجسم</strong></p></td></tr><tr><td style="height:20.55pt; vertical-align:top; width:123.2pt"><p style="text-align:center" dir="RTL"><strong>دون 50 كلغم</strong></p></td><td style="border-color:black; height:20.55pt; vertical-align:top; width:91.9pt"><p style="text-align:center" dir="RTL"><strong>50-60 كلغم</strong></p></td><td style="border-color:black; height:20.55pt; vertical-align:top; width:95.8pt"><p style="text-align:justify" dir="RTL"><strong>أكثر من 60 كلغم</strong></p></td></tr><tr><td style="border-color:black; height:32.05pt; vertical-align:top; width:66.75pt" rowspan="2"><p style="text-align:justify" dir="RTL"><strong>&nbsp;</strong></p><p style="text-align:center" dir="RTL"><strong>العمر</strong></p></td><td style="height:32.05pt; vertical-align:top; width:86.65pt"><p style="text-align:center" dir="RTL">36 عامًا أو أصغر</p></td><td style="height:32.05pt; vertical-align:top; width:123.2pt"><p style="text-align:center" dir="RTL">100 ميكروغرام</p></td><td style="height:32.05pt; vertical-align:top; width:91.9pt"><p style="text-align:center" dir="RTL">100 ميكروغرام</p></td><td style="height:32.05pt; vertical-align:top; width:95.8pt"><p style="text-align:center" dir="RTL">150 ميكروغرام</p></td></tr><tr><td style="height:25.8pt; vertical-align:top; width:86.65pt"><p style="text-align:center" dir="RTL">أكثر من 36 عامًا</p></td><td style="height:25.8pt; vertical-align:top; width:123.2pt"><p style="text-align:center" dir="RTL">لم يتم دراستها</p></td><td style="height:25.8pt; vertical-align:top; width:91.9pt"><p style="text-align:center" dir="RTL">150 ميكروغرام</p></td><td style="height:25.8pt; vertical-align:top; width:95.8pt"><p style="text-align:center" dir="RTL">150 ميكروغرام</p></td></tr></tbody></table><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">خلال الأيام السبعة الأولى بعد حقن إيلونفا، يجب عدم استخدام هرمون محفّز للجريبات (مؤتلف) (rec)FSH. بعد مرور سبعة أيام على حقن إيلونفا، قد يُقرّر الطبيب متابعة دورة التحفيز بواسطة هرمون موجهة للغدد التناسلية آخر، مثل (rec)FSH. قد يستمرّ ذلك لبضعة أيّام حتى توفّر العدد الكافي من الجريبات من الحجم الملائم. يُمكن التّأكّد من ذلك بالتصوير فوق الصوتي. يتمّ عندئذ ايقاف العلاج بواسطة هذا الهرمون (rec)FSH وتبلغ البويضات مستوى النضوج من خلال إعطاء مُوجّهة الغدد التناسليّة المشيمائيّة البشريّة. يتمّ التقاط البويضات من المبيض بعد مرور ٣٤-٣٦ ساعة.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>كيفيّة إعطاء إيلونفا</strong></p><p style="text-align:justify" dir="RTL">يجب أن يتمّ العلاج بواسطة إيلونفا تحت إشراف طبيب يتمتّع بالخبرة في معالجة مشاكل الخصوبة. يجب حقن إيلونفا تحت الجلد في طيّة جلديّة (تثنى بين الإبهام والسبابة)، مباشرةً تحت السُّرَّة. يمكن إعطاء الحقنة بواسطة متخصص في الرعاية الصحية (مثلًا ممرضة)، أو زوجك، أو أنت بنفسك، بناءً على توجيهات الطبيب.</p><p style="text-align:justify" dir="RTL">استخدمي إيلونفا دائمًا بحسب توجيهات الطبيب تمامًا. عليك الرجوع إلى الطبيب أو الصيدلاني إذا كنتِ غير متأكدة. تُعطى توجيهات الاستخدام، خطوة خطوة، في نهاية هذه النشرة.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">يجب عدم حقن إيلونفا في العضل.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">يتمّ تأمين إيلونفا في حقن مُعبئة مُسبقًا مزوّدة بنظام سلامة أوتوماتيكي لمنع الإصابات بسبب الإبر بعد الاستخدام.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>في حال حقن جرعة زائدة من إيلونفا أو هرمون </strong><strong>(</strong><strong>rec)FSH</strong><strong> </strong></p><p style="text-align:justify" dir="RTL">اتّصلي بالطبيب فورًا في هذه الحالة.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>في حال نسيت حقن إيلونفا</strong></p><p style="text-align:justify" dir="RTL">في حال نسيت حقن جرعة إيلونفا في اليوم الذي من المفترض حقنها فيها، <strong>اتّصلي بالطبيب فورًا</strong>. لا تحقني إيلونفا قبل التحدّث إلى الطبيب.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">إذا كان لديك أسئلة إضافيّة حول استخدام هذا الدواء، اسألي الطبيب.</p><p style="text-align:justify" dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify" dir="RTL">على غرار جميع الأدوية، قد يسبب تناول هذا الدواء أعراضًا جانبية محتملة على الرغم من أنها قد لا تحدث لجميع الأشخاص.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>الأعراض </strong><strong>الجانبيّة الخطيرة</strong></p><p style="text-align:justify" dir="RTL">من بين المضاعفات المحتملة لعلاج بواسطة هرمون الغونادوتروفين، مثل إيلونفا، فرط تحفيز المبيضَيْن. ويمكن الحدّ من خطر التعرّض إلى هذه المضاعفة من خلال مراقبة عدد الجريبات في طور النضوج بشكل بعنايه. سيُجري طبيب تصويرًا فوق صوتيًّا للمبيضَيْن لمراقبة عدد الجريبات الناضجة بعنايه. كما يتأكّد الطبيب من مستويات الهرمون في الدم. ومن العوارض الأولى لفرط تحفيز المبيضَيْن، الألم في المعدة (البطن) والشعور بالغثيان. قد يتحوّل فرط تحفيز المبيضَيْن إلى حالة طبيّة تُعرف بمتلازمة فرط التحفيز المبيضي، التي قد تشّكل مشكلة طبيّة خطرة. في حالات أكثر خطورةً، قد يسبّب ذلك انتفاخ المبيضَيْن، وتكدّس السوائل في البطن و/أو الصدر (ممّا قد يُسبّب زيادة مفاجئة في الوزن بسبب تكدّس السوائل) أو جلطات في الأوعية الدمويّة.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">اتّصلي بالطبيب من دون أي تأخير في حال إصابتك بألم في المعدة (البطن) وفي حال تعرّضك لأي من العوارض الأخرى لفرط التحفيز المبيضي، حتى في حال حدوثها بضعة أيّام بعد إعطاء الحقنة.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">تندرج فرص التعرّض لعرض جانبي ضمن الفئات التالية:</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">الأعراض الجانبيّة الشائعة (التي قد تؤثّر على ١ من أصل ١٠ إناث):</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- فرط تحفيز المبيضَيْن</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- ألم في الحوض</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- الشعور بالغثيان</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- صُداع</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- الشعور بعدم راحة في الحوض</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- ألم في الثدَيْن</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">- الشعور بالتعب</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">الأعراض الجانبيّة غير الشائعة (التي قد تؤثّر على 1 من أصل &nbsp;100 أُنثى):</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إلتواء المبيضَيْن</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->زيادة إنزيم الكبد</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إجهاض</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم عند استخراج الخلايا البيضيّة</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم عند الخضوع للإجراء</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الإباضة السابقة لأوانها</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إنتفاخ البطن</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التقيؤ</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الإسهال</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الإمساك</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم في الظهر</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم في الثديَيْن</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التكدّم أو الألم في موقع الحقن</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الانفعاليّة</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تقلّبات مزاجيّة</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الشعور بالدوران</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الهبّات الساخنة</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">التكرار غير معروف (لا يمكن تقديره من البيانات المتاحة)</p><p style="text-align:justify" dir="RTL">-الحساسية (تفاعلات فرط الحساسية، سواء الموضعية أو في كافة الجسم، بما في ذلك طفح جلدي).</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">كما تمّ الإبلاغ عن حالات حمل خارج الرحم، والحمل المتعدّد. لا تُعتبر هذه الأعراض الجانبيّة مرتبطة باستخدام إيلونفا، إنّما بالتكنولوجيا الانجابيّة المساعدة أو الحمل اللاحق.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">في حالات نادرة، تنفصل جلطات الدم التي تتشكّل في داخل شريان دموي إلى أجزاء وتسير في مجرى الدم فتسدّ وعاءً دمويًّا آخر (انصمام خثاري)، سببها العلاج بالإيلونفا، كما هي الحال مع هرمونات غونادوتروفين أخرى.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>الإبلاغ عن الأعراض الجانبيّة المحتملة:</strong></p><p style="text-align:justify" dir="RTL">اتّصل بالطبيب أو الصيدلي في حال تعرّضك لأي أعراض جانبيّة محتملة بالإضافة إلى تلك غير المذكورة في هذه النشرة. يمكنك الإبلاغ عن الأعراض الجانبيّة مباشرة من خلال &quot; المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء&quot;</p><p style="text-align:justify" dir="RTL">&nbsp;يُمكنك تأمين المزيد من المعلومات حول سلامة هذا الدواء من خلال الابلاغ عن الأعراض الجانبيّة.</p><p style="text-align:justify" dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify" dir="RTL">يُحفظ هذا الدواء بعيدًا عن متناول أيدي ومرأى الأطفال.</p><p style="text-align:justify" dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية و الشريط بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p style="text-align:justify" dir="RTL"><strong>&nbsp;</strong></p><p style="text-align:justify" dir="RTL"><strong>التخزين لدى الصيدلي</strong></p><p style="text-align:justify" dir="RTL">يُحفظ في الثلاجة في درجة حرارة من ٢ إلى ۸ درجة مئوية. لا يجمد.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>التخزين لدى المريضة</strong></p><p style="text-align:justify" dir="RTL">أمامك خياران:</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]--><strong>1.&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]-->يُحفظ في الثلاجة في درجة حرارة من ٢ إلى ۸ درجة مئوية. لا يجمد.</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">2. يُحفظ في درجة حرارة أقل من أو تعادل 30 درجة مئوية لمدّة لا تتخطّى الشهر. دوّني تاريخ البدء بتخزين المنتَج خارج الثلاجة ، يستخدم في غضون شهر واحد من هذا التاريخ.</p><p style="text-align:justify" dir="RTL">تُحفظ الحقنة في العبوة الأصلية لحمايتها من الضوء.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL"><strong>لا تستخدمِي إيلونفا:</strong></p><p style="text-align:justify" dir="RTL">- إذا تمّ تخزينه خارج الثلاجة لأكثر من شهر</p><p style="text-align:justify" dir="RTL">- إذا تمّ تخزينه خارج الثلاجة بدرجة حرارة تتخطّى 30 درجة مئويّة</p><p style="text-align:justify" dir="RTL">- إذا لاحظتِ بأن المحلول غير شفاف.</p><p style="text-align:justify" dir="RTL">- إذا لاحظتِ بأن الحقنة أو الإبرة تالفة.</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسألي الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير لحماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify" dir="RTL"><strong>يحتوي إيلونفا على</strong></p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المادة الفاعلة هي كوريفوليتروبين ألفا.</p><p style="margin-left:0in; margin-right:.5in; text-align:justify; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;تحتوي كل حقنة من إيلونفا ١٠٠ ميكروغرام محلول للحقن مُعبئة مُسبقًا على ١٠٠ ميكروغرام في محلول 5&sbquo;0 &nbsp;مل للحقن.</p><p style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تحتوي كل حقنة من إيلونفا 150 ميكروغرام محلول للحقن مُعبئة مُسبقًا على 150 ميكروغرام في محلول 5&sbquo;0 مل للحقن.</p><p style="margin-left:0in; margin-right:.5in; text-align:justify" dir="RTL">&nbsp;</p><p style="text-align:justify" dir="RTL">- المكوّنات الأخرى هي: ستيرات الصوديوم ثنائي الهيدرات (68&sbquo;3 ملغم) ، سكروز (35 ملغم) ، بوليسوربات 20 (1&sbquo;. ملغم)، ل- الميثيونين (25&sbquo;. ملغم) ، هيدروكسيد الصوديوم (لتعديل درجة الحموضة) ، حمض الهيدروكلوريك (لتعديل درجة الحموضة)، الماء للحقن (5&sbquo;. مل).</p><p style="text-align:justify" dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify" dir="RTL">إيلونفا شفاف عديم اللون محلول للحقن (حقنة) في إبرة مسبقة التعبئة مزوّدة بجهاز سلامة أوتوماتيكي، ممّا يمنع وقوع إصابات بسبب وخز الإبر بعد الاستخدام. يتمّ تعبئة الحقنة مع إبرة حقن معقمة. تحتوي كل حقنة على 5&sbquo;0 مل من المحلول.</p><p style="text-align:justify" dir="RTL">تتوافر الحقنة الواحدة مسبقة التعبئة في عبوات مفردة (احادية).</p><p style="text-align:justify" dir="RTL">إيلونفا متوافر في جرعيتن: 100 ميكروجرام و 150 ميكروجرام محلول للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right" dir="RTL"><strong>الشركة</strong><strong> </strong><strong>المالكة</strong><strong> </strong><strong>لحقوق</strong><strong> </strong><strong>التسويق</strong><strong>:</strong></p><p style="text-align:justify" dir="RTL">ميرك شارب ودوم المحدودة،</p><p style="text-align:justify" dir="RTL">طريق هيرتفورد، هوديسدون،</p><p style="text-align:justify" dir="RTL">&nbsp;هيرتفوردشاير إي إن ١١ ٩ بي يو،</p><p style="text-align:justify" dir="RTL">المملكة المتحدة</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL"><strong>الشركة الصانعة:</strong></p><p style="text-align:right" dir="RTL">فيتر فارما- فيرتيجونج جي إم بي إتش وشركاه كي جي،شوتزنتراسا 87 و 99-101 ، 88212 رافينسيبرج، المانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            لقد تمت مراجعة هذه النشرة بتاريخ نوفمبر 2017
الإصدار رقم (2)



        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Elonva 100 micrograms solution for injection 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Elonva 100 micrograms solution for injection
Each pre-filled syringe contains 100 micrograms of corifollitropin alfa* in 0.5 mL solution for injection.

*corifollitropin alfa is a glycoprotein produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.

Excipient(s) with known effect:
This medicinal product contains less than 1 mmol (23 mg) sodium per injection, i.e., essentially ‘sodium-free’.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).

Clear and colourless aqueous solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]--><strong>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>Therapeutic indications</strong></p><p><strong>&nbsp;</strong></p><p>Elonva is indicated for Controlled Ovarian Stimulation (COS) in combination with a Gonadotropin Releasing Hormone (GnRH) antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if !supportLists]-->1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Posology and method of administration</p><p><strong>&nbsp;</strong></p><p>Treatment with Elonva should be initiated under the supervision of a physician experienced in the treatment of fertility problems.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>In the treatment of women of reproductive age, the dose of Elonva is based on weight and age.</p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:19.0pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->A single 100-microgram dose is recommended in women who weigh less than or equal to 60 kilograms and who are 36 years of age or younger.</p><p>&nbsp;</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->A single 150-microgram dose is recommended in women:</p><p style="margin-left:62.55pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->who weigh more than 60 kilograms, regardless of age.</p><p style="margin-left:62.55pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->who weigh 50 kilograms or more and who are older than 36 years of age.</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:0in">Women older than 36 years of age who weighed less than 50 kilograms were not studied.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:13.2pt; vertical-align:top; width:171.6pt" rowspan="2" colspan="2"><p>&nbsp;</p></td><td style="border-color:black; height:13.2pt; vertical-align:top; width:292.7pt" colspan="3"><p style="margin-left:.05pt; text-align:center">Body Weight</p></td></tr><tr><td style="height:13.1pt; vertical-align:top; width:105.0pt"><p style="margin-left:17.45pt">Less than 50 kg</p></td><td style="border-color:black; height:13.1pt; vertical-align:top; width:91.9pt"><p style="margin-left:22.1pt">50 &ndash; 60 kg</p></td><td style="border-color:black; height:13.1pt; vertical-align:top; width:95.75pt"><p style="margin-left:10.95pt">More than 60 kg</p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:74.75pt" rowspan="2"><p>&nbsp;</p><p style="margin-left:5.1pt">Age</p></td><td style="height:25.8pt; vertical-align:top; width:96.85pt"><p style="margin-left:30.05pt; margin-right:23.6pt; text-indent:-6.5pt">36 years or younger</p></td><td style="height:25.8pt; vertical-align:top; width:105.0pt"><p style="margin-left:16.25pt">100 micrograms</p></td><td style="height:25.8pt; vertical-align:top; width:91.9pt"><p style="margin-left:9.65pt">100 micrograms</p></td><td style="height:25.8pt; vertical-align:top; width:95.75pt"><p style="margin-left:11.7pt">150 micrograms</p></td></tr><tr><td style="height:25.9pt; vertical-align:top; width:96.85pt"><p style="margin-left:36.55pt; margin-right:17.7pt; text-indent:-18.75pt">Older than 36 years</p></td><td style="height:25.9pt; vertical-align:top; width:105.0pt"><p style="margin-left:25.25pt">Not studied.</p></td><td style="height:25.9pt; vertical-align:top; width:91.9pt"><p style="margin-left:9.65pt">150 micrograms</p></td><td style="height:25.9pt; vertical-align:top; width:95.75pt"><p style="margin-left:11.7pt">150 micrograms</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:15.25pt">The recommended doses of Elonva have only been established in a treatment cycle with a GnRH antagonist that was administered from stimulation day 5 or day 6 onwards (see also sections 4.1, 4.4, and 5.1).</p><p>&nbsp;</p><p style="margin-left:10.9pt">Stimulation day 1:</p><p style="margin-left:10.9pt; margin-right:18.25pt">Elonva should be administered as a single subcutaneous injection, preferably in the abdominal wall, during the early follicular phase of the menstrual cycle.</p><p>&nbsp;</p><p style="margin-left:10.9pt">Stimulation day 5 or 6:</p><p style="margin-left:10.9pt; margin-right:15.25pt">Treatment with a GnRH antagonist should be started on stimulation day 5 or day 6 depending on the ovarian response, i.e. the number and size of growing follicles. The concurrent determination of serum oestradiol levels may also be useful. The GnRH antagonist is used to prevent premature Luteinising Hormone (LH) surges.</p><p>&nbsp;</p><p style="margin-left:10.9pt">Stimulation day 8:</p><p style="margin-left:10.9pt; margin-right:18.25pt">Seven days after the injection with Elonva on stimulation day 1, COS treatment may be continued with daily injections of (recombinant) Follicle Stimulating Hormone [(rec)FSH] until the criterion for triggering final oocyte maturation (3 follicles &ge; 17 mm) has been reached. The daily dose of (rec)FSH</p><p style="margin-left:10.9pt">may depend on the ovarian response. In normal responders a daily dose of 150 IU (rec)FSH is advised.</p><p style="margin-left:10.9pt; margin-right:19.05pt">Administration of (rec)FSH on the day of human Chorionic Gonadotropin (hCG) administration can be omitted, depending on the ovarian response. In general, adequate follicular development is achieved on average by the ninth day of treatment (range 6 to 18 days).</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:18.25pt">As soon as three follicles &sup3; 17 mm are observed, a single injection of 5,000 up to 10,000 IU hCG is administered the same day or the day thereafter to induce final oocyte maturation. In case of an excessive ovarian response, see the recommendations given in section 4.4 in order to reduce the risk for developing ovarian hyperstimulation syndrome (OHSS).</p><p>&nbsp;</p><p style="margin-left:10.9pt"><em>Special populations</em></p><p><em>&nbsp;</em></p><p style="margin-left:10.9pt"><u>Renal impairment</u></p><p style="margin-left:10.9pt; margin-right:18.25pt">No clinical studies have been performed in patients with renal insufficiency. Since the rate of elimination of corifollitropin alfa may be reduced in patients with renal insufficiency, the use of Elonva in these women is not recommended (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p style="margin-left:10.9pt"><u>Hepatic impairment</u></p><p style="margin-left:10.9pt; margin-right:15.25pt">Although data in hepatically impaired patients are not available, hepatic impairment is unlikely to affect the elimination of corifollitropin alfa (see section 5.2).</p><p>&nbsp;</p><p style="margin-left:10.9pt"><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p style="margin-left:10.9pt; margin-right:22.35pt">There is no relevant use of Elonva within the approved indication in the paediatric population. <u>Method of administration</u></p><p style="margin-left:10.9pt; margin-right:18.25pt">Subcutaneous injection of Elonva may be carried out by the woman herself or her partner, provided that proper instructions are given by the physician. Self administration of Elonva should only be performed by women who are well-motivated, adequately trained and with access to expert advice.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3	Contraindications

	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
	Tumours of the ovary, breast, uterus, pituitary or hypothalamus.
	Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause.
	Primary ovarian failure.
	Ovarian cysts or enlarged ovaries.
	A history of Ovarian Hyperstimulation Syndrome (OHSS).
	A previous COS cycle that resulted in more than 30 follicles 11 mm measured by ultrasound examination.
	A basal antral follicle count > 20.
	Fibroid tumours of the uterus incompatible with pregnancy.
	Malformations of the reproductive organs incompatible with pregnancy.
	Polycystic ovarian syndrome (PCOS).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Infertility evaluation before starting treatment</u></p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:14.2pt">Before starting treatment, the couple&rsquo;s infertility should be assessed as appropriate. In particular, women should be evaluated for hypothyroidism, adrenocortical insufficiency, hyperprolactinemia and pituitary or hypothalamic tumours, and appropriate specific treatment</p><p style="margin-left:34.2pt; margin-right:3.85pt">given. Medical conditions that contraindicate pregnancy should also be evaluated before starting treatment with Elonva.</p><p>&nbsp;</p><p><u>Dosing during the stimulation cycle</u></p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:14.2pt">Elonva is intended for single subcutaneous injection only. Additional injections of Elonva should not be given within the same treatment cycle. (See also section 4.2.)</p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:14.2pt">After administration of Elonva, no additional FSH-containing product should be administered prior to stimulation day 8 (see also section 4.2).</p><p>&nbsp;</p><p><u>Renal insufficiency</u></p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:14.2pt">In patients with mild, moderate or severe renal insufficiency the rate of elimination of corifollitropin alfa may be reduced (see sections 4.2 and 5.2). Therefore, the use of Elonva in these women is not recommended.</p><p>&nbsp;</p><p><u>Not recommended with a GnRH agonist protocol</u></p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:14.6pt">There are limited data on the use of Elonva in combination with a GnRH agonist. Results of a small uncontrolled study suggest a higher ovarian response than in combination with a GnRH antagonist. Therefore, the use of Elonva is not recommended in combination with a GnRH agonist (see also section 4.2).</p><p>&nbsp;</p><p><u>Ovarian hyperstimulation syndrome (OHSS)</u></p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:9.0pt">OHSS is a medical event distinct from uncomplicated ovarian enlargement. Clinical signs and symptoms of mild and moderate OHSS are abdominal pain, nausea, diarrhoea, mild to moderate enlargement of ovaries and ovarian cysts. Severe OHSS may be life-threatening. Clinical signs and symptoms of severe OHSS are large ovarian cysts, acute abdominal pain, ascites, pleural effusion, hydrothorax, dyspnoea, oliguria, haematological abnormalities and weight gain. In rare instances, venous or arterial thromboembolism may occur in association with OHSS. Transient liver function test abnormalities suggestive of hepatic dysfunction with or without morphologic changes on liver biopsy have also been reported in association with OHSS.</p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:14.6pt">OHSS may be caused by administration of hCG and by pregnancy (endogenous hCG). Early OHSS usually occurs within 10 days after hCG administration and may be associated with an excessive ovarian response to gonadotropin stimulation. Late OHSS occurs more than 10 days after hCG administration, as a consequence of the hormonal changes with pregnancy. Because of the risk of developing OHSS, patients should be monitored for at least two weeks after hCG administration.</p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:8.05pt">Women with known risk factors for a high ovarian response may be especially prone to the development of OHSS following treatment with Elonva. For women having their first cycle of ovarian stimulation, for whom risk factors are only partially known, close observation for early signs and symptoms of OHSS is recommended.</p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:3.85pt">To reduce the risk of OHSS, ultrasonographic assessments of follicular development should be performed prior to treatment and at regular intervals during treatment. The concurrent determination of serum oestradiol levels may also be useful. In ART there is an increased risk of OHSS with 18 or more follicles of 11 mm or more in diameter. When there are 30 or more follicles in total it is advised to withhold hCG administration.</p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:3.85pt">Depending on the ovarian response, the following measures can be considered to reduce the risk of OHSS:</p><p style="margin-left:62.55pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->withhold further stimulation with a gonadotropin for a maximum of 3 days (coasting);</p><p style="margin-left:62.55pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->withhold hCG and cancel the treatment cycle;</p><p style="margin-left:62.55pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->administer a dose lower than 10,000 IU of hCG for triggering final oocyte maturation,</p><p style="margin-left:62.55pt; margin-right:14.2pt">e.g. 5,000 IU hCG or 250 micrograms rec-hCG (which is equivalent to approximately 6,500 IU);</p><p style="margin-left:62.55pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->cancel the fresh embryo transfer and cryopreserve embryos;</p><p style="margin-left:62.55pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->avoid administration of hCG for luteal phase support.</p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:29.35pt; text-align:justify">Adherence to the recommended Elonva dose and treatment cycle and careful monitoring of ovarian response is important to reduce the risk of OHSS. If OHSS develops, standard and appropriate management of OHSS should be implemented and followed.</p><p>&nbsp;</p><p><u>Ovarian torsion</u></p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:14.2pt">Ovarian torsion has been reported after treatment with gonadotropins, including Elonva. Ovarian torsion may be related to other conditions, such as OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, and previous or current ovarian cysts. Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion.</p><p>&nbsp;</p><p><u>Multiple pregnancy</u></p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:8.05pt">Multiple pregnancies and births have been reported for all gonadotropin treatments, including Elonva. The woman and her partner should be advised of the potential risks for the mother (pregnancy and delivery complications) and the neonate (low birth weight) before starting treatment. In women undergoing ART procedures the risk of multiple pregnancy is mainly related to the number of embryos transferred.</p><p>&nbsp;</p><p><u>Ectopic pregnancy</u></p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:14.6pt">Infertile women undergoing ART have an increased incidence of ectopic pregnancies. It is important to have early ultrasound confirmation that a pregnancy is intrauterine, and to exclude the possibility of extrauterine pregnancy.</p><p>&nbsp;</p><p><u>Congenital malformations</u></p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:14.6pt">The incidence of congenital malformations after ART may be slightly higher than after spontaneous conceptions. This is thought to be due to differences in parental characteristics (e.g., maternal age, sperm characteristics) and the higher incidence of multiple pregnancies.</p><p>&nbsp;</p><p><u>Ovarian and other reproductive system neoplasms</u></p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:9.0pt">There have been reports of ovarian and other reproductive system neoplasms, both benign and malignant, in women who have undergone multiple treatment regimens for infertility treatment. It is not established whether or not treatment with gonadotropins increases the risk of these tumours in infertile women.</p><p>&nbsp;</p><p><u>Vascular complications</u></p><p>&nbsp;</p><p style="margin-left:34.2pt; margin-right:9.0pt">Thromboembolic events, both in association with and separate from OHSS, have been reported following treatment with gonadotropins, including Elonva. Intravascular thrombosis, which may originate in venous or arterial vessels, can result in reduced blood flow to vital organs or the extremities. In women with generally recognized risk factors for thromboembolic events, such</p><p style="margin-left:34.2pt; margin-right:9.0pt">as a personal or family history, severe obesity or thrombophilia, treatment with gonadotropins may further increase this risk. In these women the benefits of gonadotropin administration need to be weighed against the risks. It should be noted, however, that pregnancy itself also carries an increased risk of thrombosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:9.0pt">No interaction studies with Elonva and other medicines have been performed. Since corifollitropin alfa is not a substrate of cytochrome P450 enzymes, no metabolic interactions with other medicinal products are anticipated.</p><p>&nbsp;</p><p style="margin-right:23.6pt; text-align:justify">Elonva may cause a false positive hCG pregnancy test if the test is administered during the ovarian stimulation portion of the ART cycle. This may be due to cross-reactivity of some hCG pregnancy tests with the carboxy-terminal peptide of the beta subunit of Elonva.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:14.2pt">In case of inadvertent exposure to Elonva during pregnancy, clinical data are not sufficient to exclude an adverse outcome of pregnancy. In animal studies reproductive toxicity has been observed (see preclinical safety data in section 5.3). The use of Elonva during pregnancy is not indicated.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:178.15pt">The use of Elonva during breast-feeding is not indicated. <u>Fertility</u></p><p>Elonva is indicated for use in infertility (see section 4.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>No studies on the ability to drive and use machines have been performed.</p><p style="margin-right:9.0pt">Elonva may cause dizziness. Women should be advised that if they feel dizzy, they should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:11.9pt"><u>Summary of the safety profile</u></p><p>&nbsp;</p><p style="margin-left:11.9pt; margin-right:18.5pt">The most frequently reported adverse reactions during treatment with Elonva in clinical trials (N=2,397) are pelvic discomfort (6.0%), OHSS (4.3%, see also section 4.4), headache (4.0%), pelvic pain (2.9%), nausea (2.3%), fatigue (1.5%), and breast tenderness (1.3%).</p><p>&nbsp;</p><p style="margin-left:11.9pt"><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p style="margin-left:11.9pt; margin-right:18.5pt">The table below displays the main adverse reactions in women treated with Elonva in clinical trials and post-marketing surveillance according to system organ class and frequency; very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), and not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p style="margin-left:5.75pt"><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.5pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1053" style='width:465.85pt;
 height:1.55pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9317,31">
 <v:group id="_x0000_s1054" style='position:absolute;left:15;top:15;width:9286;
  height:2' coordorigin="15,15" coordsize="9286,2">
  <v:shape id="_x0000_s1055" style='position:absolute;left:15;top:15;width:9286;
   height:2' coordorigin="15,15" coordsize="9286,0" path="m15,15r9286,e"
   filled="f" strokeweight="1.54pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if !vml]--><img width="622" height="3" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image001.gif" /><!--[endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.5pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:465.85pt;
 height:1.55pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>System organ class&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reaction</p><p style="margin-left:5.75pt"><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.5pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1050" style='width:465.85pt;
 height:1.55pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9317,31">
 <v:group id="_x0000_s1051" style='position:absolute;left:15;top:15;width:9286;
  height:2' coordorigin="15,15" coordsize="9286,2">
  <v:shape id="_x0000_s1052" style='position:absolute;left:15;top:15;width:9286;
   height:2' coordorigin="15,15" coordsize="9286,0" path="m15,15r9286,e"
   filled="f" strokeweight="1.54pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if !vml]--><img width="622" height="3" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image001.gif" /><!--[endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.5pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:465.85pt;
 height:1.55pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p style="margin-left:321.6pt; margin-right:15.1pt; text-align:justify; text-indent:-309.75pt"><strong>Immune system disorders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Not known Hypersensitivity reactions, both local and generalised, including rash*</p><p style="margin-left:6.2pt"><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1047" style='width:464.9pt;
 height:.6pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9298,12">
 <v:group id="_x0000_s1048" style='position:absolute;left:6;top:6;width:9286;
  height:2' coordorigin="6,6" coordsize="9286,2">
  <v:shape id="_x0000_s1049" style='position:absolute;left:6;top:6;width:9286;
   height:2' coordorigin="6,6" coordsize="9286,0" path="m6,6r9285,e" filled="f"
   strokeweight=".58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if !vml]--><img width="621" height="1" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image002.gif" /><!--[endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1027" type="#_x0000_t75" style='width:464.9pt;
 height:.6pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p style="margin-left:11.9pt"><strong>Psychiatric disorders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mood swings</p><p>&nbsp;</p><p style="margin-left:6.1pt"><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1044" style='width:465.1pt;
 height:.85pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9302,17">
 <v:group id="_x0000_s1045" style='position:absolute;left:8;top:8;width:9286;
  height:2' coordorigin="8,8" coordsize="9286,2">
  <v:shape id="_x0000_s1046" style='position:absolute;left:8;top:8;width:9286;
   height:2' coordorigin="8,8" coordsize="9286,0" path="m8,8r9286,e" filled="f"
   strokeweight=".82pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if !vml]--><img width="621" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image003.gif" /><!--[endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1028" type="#_x0000_t75" style='width:465.1pt;
 height:.85pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p style="margin-left:11.9pt"><strong>Nervous system </strong><strong>disorders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p style="margin-left:166.7pt">Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p style="margin-left:6.1pt"><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1041" style='width:465.1pt;
 height:.85pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9302,17">
 <v:group id="_x0000_s1042" style='position:absolute;left:8;top:8;width:9286;
  height:2' coordorigin="8,8" coordsize="9286,2">
  <v:shape id="_x0000_s1043" style='position:absolute;left:8;top:8;width:9286;
   height:2' coordorigin="8,8" coordsize="9286,0" path="m8,8r9286,e" filled="f"
   strokeweight=".82pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if !vml]--><img width="621" height="1" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image004.gif" /><!--[endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1029" type="#_x0000_t75" style='width:465.1pt;
 height:.85pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p style="margin-left:11.9pt"><strong>Vascular disorders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hot flush</p><p>&nbsp;</p><p style="margin-left:6.1pt"><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1038" style='width:465.1pt;
 height:.85pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9302,17">
 <v:group id="_x0000_s1039" style='position:absolute;left:8;top:8;width:9286;
  height:2' coordorigin="8,8" coordsize="9286,2">
  <v:shape id="_x0000_s1040" style='position:absolute;left:8;top:8;width:9286;
   height:2' coordorigin="8,8" coordsize="9286,0" path="m8,8r9286,e" filled="f"
   strokeweight=".82pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if !vml]--><img width="621" height="1" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image005.gif" /><!--[endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1030" type="#_x0000_t75" style='width:465.1pt;
 height:.85pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p style="margin-left:11.9pt"><strong>Gastrointestinal disorders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p style="margin-left:321.6pt; margin-right:55.75pt; text-indent:-154.95pt"><!--[if gte vml 1]><v:group id="_x0000_s1056" style='position:absolute;
 left:0;text-align:left;margin-left:65.5pt;margin-top:38.7pt;width:464.3pt;
 height:.1pt;z-index:1264;mso-position-horizontal-relative:page' coordorigin="1310,774"
 coordsize="9286,2">
 <v:shape id="_x0000_s1057" style='position:absolute;left:1310;top:774;width:9286;
  height:2' coordorigin="1310,774" coordsize="9286,0" path="m1310,774r9286,e"
  filled="f" strokeweight=".82pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="621" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image006.gif" /><!--[endif]-->Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal distension, vomiting, diarrhoea, constipation</p><p>&nbsp;</p><p>Musculoskeletal and connective tissue disorders</p><p>&nbsp;</p><p style="margin-left:11.9pt; margin-right:0in">Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:6.1pt"><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1035" style='width:465.1pt;
 height:.85pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9302,17">
 <v:group id="_x0000_s1036" style='position:absolute;left:8;top:8;width:9286;
  height:2' coordorigin="8,8" coordsize="9286,2">
  <v:shape id="_x0000_s1037" style='position:absolute;left:8;top:8;width:9286;
   height:2' coordorigin="8,8" coordsize="9286,0" path="m8,8r9286,e" filled="f"
   strokeweight=".82pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if !vml]--><img width="621" height="1" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image005.gif" /><!--[endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1031" type="#_x0000_t75" style='width:465.1pt;
 height:.85pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Pregnancy, puerperium and</p><p style="margin-left:11.9pt; margin-right:0in"><strong>perinatal conditions</strong></p><p>&nbsp;</p><p style="margin-left:11.9pt">Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abortion spontaneous</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:6.1pt"><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1032" style='width:465.1pt;
 height:.85pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9302,17">
 <v:group id="_x0000_s1033" style='position:absolute;left:8;top:8;width:9286;
  height:2' coordorigin="8,8" coordsize="9286,2">
  <v:shape id="_x0000_s1034" style='position:absolute;left:8;top:8;width:9286;
   height:2' coordorigin="8,8" coordsize="9286,0" path="m8,8r9286,e" filled="f"
   strokeweight=".82pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if !vml]--><img width="621" height="1" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image007.gif" /><!--[endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1032" type="#_x0000_t75" style='width:465.1pt;
 height:.85pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Reproductive system and</p><p style="margin-left:11.9pt"><strong>breast disorders</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p style="margin-left:11.9pt"><!--[if gte vml 1]><v:group id="_x0000_s1058"
 style='position:absolute;left:0;text-align:left;margin-left:65.5pt;
 margin-top:-.3pt;width:464.3pt;height:.1pt;z-index:1288;
 mso-position-horizontal-relative:page' coordorigin="1310,-6" coordsize="9286,2">
 <v:shape id="_x0000_s1059" style='position:absolute;left:1310;top:-6;width:9286;
  height:2' coordorigin="1310,-6" coordsize="9286,0" path="m1310,-6r9286,e"
  filled="f" strokeweight=".82pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="621" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image008.gif" /><!--[endif]--><strong>General disorders and</strong><strong> </strong><strong>administration site conditions</strong></p><p>&nbsp;</p><p style="margin-left:166.8pt; text-indent:-154.95pt">Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OHSS, pelvic pain, pelvic</p><p style="margin-left:166.8pt">discomfort, breast tenderness</p><p style="margin-left:166.8pt; margin-right:27.2pt; text-indent:-154.95pt">Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ovarian torsion, adnexa uteri pain, premature ovulation, breast pain</p><p style="margin-left:11.9pt; margin-right:0in">Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue</p><p>&nbsp;</p><p style="margin-left:166.8pt; margin-right:27.2pt; text-indent:-154.95pt">Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site haematoma, injection site pain, irritability</p><p>&nbsp;</p><p style="margin-left:6.1pt"><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1029" style='width:465.1pt;
 height:.85pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9302,17">
 <v:group id="_x0000_s1030" style='position:absolute;left:8;top:8;width:9286;
  height:2' coordorigin="8,8" coordsize="9286,2">
  <v:shape id="_x0000_s1031" style='position:absolute;left:8;top:8;width:9286;
   height:2' coordorigin="8,8" coordsize="9286,0" path="m8,8r9286,e" filled="f"
   strokeweight=".82pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if !vml]--><img width="621" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image009.gif" /><!--[endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1033" type="#_x0000_t75" style='width:465.1pt;
 height:.85pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p style="margin-left:321.6pt; margin-right:.5in; text-indent:-309.75pt"><!--[if gte vml 1]><v:group id="_x0000_s1060"
 style='position:absolute;left:0;text-align:left;margin-left:65.5pt;
 margin-top:38.25pt;width:464.3pt;height:.1pt;z-index:1312;
 mso-position-horizontal-relative:page' coordorigin="1310,765" coordsize="9286,2">
 <v:shape id="_x0000_s1061" style='position:absolute;left:1310;top:765;width:9286;
  height:2' coordorigin="1310,765" coordsize="9286,0" path="m1310,765r9286,e"
  filled="f" strokeweight=".82pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="621" height="1" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image010.gif" /><!--[endif]--><strong>Investigations&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alanine aminotransferase increased, aspartate aminotransferase increased</p><p>&nbsp;</p><p>Injury, poisoning and procedural complications</p><p>&nbsp;</p><p style="margin-left:11.9pt; margin-right:0in">Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Procedural pain</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.0pt"><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.5pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1026" style='width:466.55pt;
 height:1.55pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9331,31">
 <v:group id="_x0000_s1027" style='position:absolute;left:15;top:15;width:9300;
  height:2' coordorigin="15,15" coordsize="9300,2">
  <v:shape id="_x0000_s1028" style='position:absolute;left:15;top:15;width:9300;
   height:2' coordorigin="15,15" coordsize="9300,0" path="m15,15r9300,e"
   filled="f" strokeweight="1.54pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if !vml]--><img width="623" height="3" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image011.gif" /><!--[endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.5pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1034" type="#_x0000_t75" style='width:466.55pt;
 height:1.55pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p style="margin-left:11.9pt">*Adverse reactions were identified through post-marketing surveillance.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:12.05pt">In addition, ectopic pregnancy and multiple gestations have been reported. These are considered to be related to ART or subsequent pregnancy.</p><p>&nbsp;</p><p style="margin-right:17.8pt">In rare instances, thromboembolism has been associated with Elonva therapy as with other gonadotropins.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:12.05pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p style="margin-left:5.9pt; margin-right:12.05pt">&nbsp;</p><p style="margin-left:5.9pt; margin-right:12.05pt"><strong>To report any side effect(s):</strong></p><p style="margin-left:4.5pt; text-indent:9.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Saudi Arabia: </u></p><p style="text-align:justify; text-indent:9.0pt">The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA</p><p style="text-align:justify; text-indent:9.0pt">o Fax: +966-11-205-7662</p><p style="text-align:justify; text-indent:9.0pt">o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p style="text-align:justify; text-indent:9.0pt">o Toll free phone: 8002490000</p><p style="text-align:justify; text-indent:9.0pt">o E-mail: npc.drug@sfda.gov.sa</p><p style="text-align:justify; text-indent:9.0pt">o Website: www.sfda.gov.sa/npc</p><p style="margin-left:4.5pt; text-indent:9.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Other GCC States: </u></p><p style="margin-left:0in; margin-right:0in">Please contact the relevant competent authority.</p><p style="margin-left:5.9pt; margin-right:12.05pt">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:17.8pt">More than one injection of Elonva within one treatment cycle or too high a dose of Elonva and/or (rec)FSH may increase the risk of OHSS. For measures to reduce the risk of OHSS see section 4.4.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]--><strong>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>Pharmacodynamic properties</strong></p><p><strong>&nbsp;</strong></p><p style="margin-right:17.8pt">Pharmacotherapeutic group: sex hormones and modulators of the genital system, gonadotropins, ATC code: G03GA09</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:6.25pt">Corifollitropin alfa is designed as a sustained follicle stimulant with the same pharmacodynamic profile as (rec)FSH, but with a markedly prolonged duration of FSH activity. Due to its ability to initiate&nbsp;&nbsp;&nbsp; &nbsp;and sustain multiple follicular growth for an entire week, a single subcutaneous injection of the recommended dose of Elonva may replace the first seven injections of any daily (rec)FSH preparation in a COS treatment cycle. The long duration of FSH activity was achieved by adding the</p><p style="margin-left:5.9pt; margin-right:17.8pt">carboxy-terminal peptide of the &beta;-subunit of human chorionic gonadotropin (hCG) to the &beta;-chain of human FSH. Corifollitropin alfa does not display any intrinsic LH/hCG activity.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:12.05pt">In three randomized, double-blind, clinical trials, treatment with a single subcutaneous injection of Elonva, 100 micrograms (ENSURE study) or 150 micrograms (ENGAGE and PURSUE study), for the first seven days of COS was compared to treatment with a daily dose of 150, 200, or 300 IU of recFSH, respectively. Pituitary suppression with a GnRH antagonist (ganirelix acetate injection at a daily dose of 0.25 mg) was used in each of the three clinical trials.</p><p>&nbsp;</p><p style="margin-right:11.4pt">In the ENSURE study, 396 healthy normal ovulatory women, aged 18 to 36 years with a body weight less than or equal to 60 kg, were treated for one cycle with 100 micrograms of Elonva and pituitary suppression with a GnRH antagonist as part of an ART program. The primary efficacy endpoint was number of oocytes retrieved. The median total duration of stimulation was 9 days for both groups, indicating that two days of recFSH were required to complete ovarian stimulation from stimulation day 8 onwards (recFSH was given on the day of hCG for this study).</p><p>&nbsp;</p><p style="margin-right:17.8pt">In the ENGAGE Study, 1,506 healthy normal ovulatory women, aged 18 to 36 years with a body weight greater than 60 kg and less than or equal to 90 kg, were treated for one cycle with</p><p style="margin-right:17.8pt">150 micrograms of Elonva and pituitary suppression with a GnRH antagonist as part of an ART program. The co-primary efficacy endpoints were ongoing pregnancy rate and number of oocytes</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:18.25pt">retrieved. The median total duration of stimulation was 9 days for both groups, indicating that two days of recFSH were required to complete ovarian stimulation from stimulation day 8 onwards (recFSH was given on the day of hCG for this study).</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:17.2pt">In the PURSUE study, 1,390 healthy normal ovulatory women, aged 35 to 42 years with a body weight greater than or equal to 50 kg, were treated for one cycle with 150 micrograms of Elonva and pituitary suppression with a GnRH antagonist as part of an ART program. The primary efficacy endpoint was vital pregnancy rate. The number of oocytes retrieved was a key secondary efficacy endpoint. The median total duration of stimulation was 9 days for both groups, indicating that one day of recFSH was required to complete ovarian stimulation from stimulation day 8 onwards (no recFSH was given on the day of hCG for this study).</p><p>&nbsp;</p><p style="margin-left:10.9pt"><em>Number of oocytes retrieved</em></p><p style="margin-left:10.9pt; margin-right:18.25pt">In all three studies, treatment with a single injection of Elonva, 100 or 150 micrograms, for the first seven days of COS, resulted in a higher number of oocytes retrieved compared with a daily dose of recFSH. However, the differences were within the predefined equivalence (ENGAGE and ENSURE) or non-inferiority (PURSUE) margins. See Table 1 below.</p><p>&nbsp;</p><p>Table 1: Mean Number of Oocytes Retrieved from ENSURE, ENGAGE, and PURSUE Intent-to-Treat Population (ITT)</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:76.45pt; vertical-align:top; width:65.75pt"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p style="margin-left:5.1pt"><strong>Parameter</strong></p></td><td style="border-color:black; height:76.45pt; vertical-align:top; width:132.6pt" colspan="2"><p><strong>&nbsp;</strong></p><p style="margin-right:.1pt; text-align:center"><strong>ENSURE</strong></p><p style="margin-left:10.25pt; margin-right:10.25pt; text-align:center; text-indent:-.05pt">(18-36 years of age) (body weight less than or equal to 60 kg)</p></td><td style="border-color:black; height:76.45pt; vertical-align:top; width:133.1pt" colspan="2"><p style="margin-right:.25pt; text-align:center"><strong>ENGAGE</strong></p><p style="margin-left:9.4pt; margin-right:9.55pt; text-align:center; text-indent:.05pt">(18-36 years of age) (body weight greater than 60 kg and less than or equal to 90 kg)</p></td><td style="border-color:black; height:76.45pt; vertical-align:top; width:132.85pt" colspan="2"><p style="margin-left:0in; margin-right:.1pt; text-align:center"><strong>PURSUE</strong></p><p style="margin-left:9.3pt; margin-right:9.4pt; text-align:center; text-indent:.05pt">(35-42 years of age) (body weight greater than or equal to 50 kg)</p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:65.75pt"><p>&nbsp;</p></td><td style="height:25.8pt; vertical-align:top; width:66.0pt"><p style="margin-left:17.1pt; margin-right:16.05pt; text-indent:-1.0pt"><strong>Elonva</strong><strong> </strong><strong>100 &micro;g</strong></p></td><td style="height:25.8pt; vertical-align:top; width:66.6pt"><p style="margin-left:17.2pt; margin-right:14.9pt; text-indent:-2.3pt"><strong>recFSH</strong><strong> </strong><strong>150 IU</strong></p></td><td style="height:25.8pt; vertical-align:top; width:66.5pt"><p style="margin-left:17.3pt; margin-right:16.25pt; text-indent:-1.0pt"><strong>Elonva</strong><strong> </strong><strong>150 &micro;g</strong></p></td><td style="height:25.8pt; vertical-align:top; width:66.6pt"><p style="margin-left:17.1pt; margin-right:15.0pt; text-indent:-2.3pt"><strong>recFSH</strong><strong> </strong><strong>200 IU</strong></p></td><td style="height:25.8pt; vertical-align:top; width:66.35pt"><p style="margin-left:17.2pt; margin-right:16.25pt; text-indent:-1.0pt"><strong>Elonva</strong><strong> </strong><strong>150 &micro;g</strong></p></td><td style="height:25.8pt; vertical-align:top; width:66.5pt"><p style="margin-left:17.2pt; margin-right:14.75pt; text-indent:-2.3pt"><strong>recFSH</strong><strong> </strong><strong>300 IU</strong></p></td></tr><tr><td style="border-color:black; height:14.3pt; vertical-align:top; width:65.75pt"><p>&nbsp;</p></td><td style="height:14.3pt; vertical-align:top; width:66.0pt"><p style="margin-left:17.35pt; margin-right:0in">N=268</p></td><td style="height:14.3pt; vertical-align:top; width:66.6pt"><p style="margin-left:17.7pt; margin-right:0in">N=128</p></td><td style="height:14.3pt; vertical-align:top; width:66.5pt"><p style="margin-left:17.55pt; margin-right:0in">N=756</p></td><td style="height:14.3pt; vertical-align:top; width:66.6pt"><p style="margin-left:17.55pt; margin-right:0in">N=750</p></td><td style="height:14.3pt; vertical-align:top; width:66.35pt"><p style="margin-left:17.45pt; margin-right:0in">N=694</p></td><td style="height:14.3pt; vertical-align:top; width:66.5pt"><p style="margin-left:17.55pt; margin-right:0in">N=696</p></td></tr><tr><td style="border-color:black; height:38.4pt; vertical-align:top; width:65.75pt"><p style="margin-left:5.1pt; margin-right:14.35pt">Mean number of oocytes</p></td><td style="height:38.4pt; vertical-align:top; width:66.0pt"><p><strong>&nbsp;</strong></p><p style="text-align:center">13.3</p></td><td style="height:38.4pt; vertical-align:top; width:66.6pt"><p><strong>&nbsp;</strong></p><p style="text-align:center">10.6</p></td><td style="height:38.4pt; vertical-align:top; width:66.5pt"><p><strong>&nbsp;</strong></p><p style="text-align:center">13.8</p></td><td style="height:38.4pt; vertical-align:top; width:66.6pt"><p><strong>&nbsp;</strong></p><p style="margin-right:.1pt; text-align:center">12.6</p></td><td style="height:38.4pt; vertical-align:top; width:66.35pt"><p><strong>&nbsp;</strong></p><p style="margin-right:.1pt; text-align:center">10.7</p></td><td style="height:38.4pt; vertical-align:top; width:66.5pt"><p><strong>&nbsp;</strong></p><p style="margin-left:.1pt; text-align:center">10.3</p></td></tr><tr><td style="border-color:black; height:38.5pt; vertical-align:top; width:65.75pt"><p style="margin-left:5.1pt; margin-right:12.8pt">Difference [95% CI]</p></td><td style="height:38.5pt; vertical-align:top; width:132.6pt" colspan="2"><p><strong>&nbsp;</strong></p><p style="margin-left:37.35pt">2.5 [1.2; 3.9]</p></td><td style="height:38.5pt; vertical-align:top; width:133.1pt" colspan="2"><p><strong>&nbsp;</strong></p><p style="margin-left:37.75pt">1.2 [0.5, 1.9]</p></td><td style="height:38.5pt; vertical-align:top; width:132.85pt" colspan="2"><p><strong>&nbsp;</strong></p><p style="margin-left:35.8pt">0.5 [-0.2, 1.2]</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p style="margin-left:10.9pt; margin-right:0in; text-align:justify"><em>Pregnancy</em><em> </em><em>from the fresh cycles of ENGAGE and PURSUE</em></p><p><em>&nbsp;</em></p><p style="margin-left:10.9pt; margin-right:14.65pt; text-align:justify">In the ENGAGE study, non-inferiority was demonstrated in ongoing pregnancy rates between Elonva and recFSH, with ongoing pregnancy rate defined as presence of at least one foetus with heart activity assessed at least 10 weeks after embryo transfer.</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:21.7pt; text-align:justify">In the PURSUE study, non-inferiority was demonstrated in vital pregnancy rate between Elonva and recFSH, with vital pregnancy rate defined as the percentage of subjects with at least one foetus with heart activity assessed 5 to 6 weeks after embryo transfer.</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:15.25pt">The pregnancy results from the fresh cycles of ENGAGE and PURSUE are summarized in Table 2 below.</p><p>&nbsp;</p><p>Table 2: Pregnancy Results from the Fresh Cycles of ENGAGE and PURSUE Intent-to-Treat Population (ITT)</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:63.7pt; vertical-align:top; width:79.9pt"><p style="margin-left:5.1pt; margin-right:0in"><strong>Parameter</strong></p></td><td style="border-color:black; height:63.7pt; vertical-align:top; width:188.15pt" colspan="3"><p style="margin-right:30.65pt; text-align:right">&dagger;</p><p style="margin-right:3.35pt; text-align:center"><strong>Fresh Cycles of </strong><strong>ENGAGE</strong></p><p style="text-align:center">(18-36 years of age)</p><p style="margin-left:14.1pt; margin-right:14.0pt; text-align:center">(body weight greater than 60 kg and less than or equal to 90 kg)</p></td><td style="border-color:black; height:63.7pt; vertical-align:top; width:196.2pt" colspan="3"><p style="text-align:center"><strong>Fresh</strong><strong> </strong><strong>Cycles of</strong><strong> </strong><strong>PURSUE</strong>&Dagger;</p><p style="margin-left:.05pt; text-align:center">(35-42 years of age)</p><p style="margin-left:16.1pt; margin-right:16.1pt; text-align:center">(body weight greater than or equal to 50 kg)</p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:79.9pt"><p>&nbsp;</p></td><td style="height:25.8pt; vertical-align:top; width:58.8pt"><p style="margin-left:13.5pt; margin-right:12.45pt; text-indent:-1.0pt"><strong>Elonva</strong><strong> </strong><strong>150 &micro;g</strong></p></td><td style="height:25.8pt; vertical-align:top; width:54.6pt"><p style="margin-left:11.2pt; margin-right:8.9pt; text-indent:-2.3pt"><strong>recFSH</strong><strong> </strong><strong>200 IU</strong></p></td><td style="height:25.8pt; vertical-align:top; width:74.75pt"><p style="margin-left:14.9pt; margin-right:12.45pt; text-indent:-2.3pt"><strong>Difference</strong><strong> </strong><strong>[95% CI]</strong></p></td><td style="height:25.8pt; vertical-align:top; width:61.45pt"><p style="margin-left:14.8pt; margin-right:13.75pt; text-indent:-1.0pt"><strong>Elonva</strong><strong> </strong><strong>150 &micro;g</strong></p></td><td style="height:25.8pt; vertical-align:top; width:62.9pt"><p style="margin-left:15.4pt; margin-right:12.95pt; text-indent:-2.3pt"><strong>recFSH</strong><strong> </strong><strong>300 IU</strong></p></td><td style="height:25.8pt; vertical-align:top; width:71.9pt"><p style="margin-left:13.35pt; margin-right:11.15pt; text-indent:-2.3pt"><strong>Difference</strong><strong> </strong><strong>[95% CI]</strong></p></td></tr><tr><td style="border-color:black; height:13.1pt; vertical-align:top; width:79.9pt"><p>&nbsp;</p></td><td style="height:13.1pt; vertical-align:top; width:58.8pt"><p style="margin-left:13.75pt; margin-right:0in">N=756</p></td><td style="height:13.1pt; vertical-align:top; width:54.6pt"><p style="margin-left:11.7pt; margin-right:0in">N=750</p></td><td style="height:13.1pt; vertical-align:top; width:74.75pt"><p>&nbsp;</p></td><td style="height:13.1pt; vertical-align:top; width:61.45pt"><p style="margin-left:15.05pt; margin-right:0in">N=694</p></td><td style="height:13.1pt; vertical-align:top; width:62.9pt"><p style="margin-left:15.75pt; margin-right:0in">N=696</p></td><td style="height:13.1pt; vertical-align:top; width:71.9pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:79.9pt"><p style="margin-left:5.1pt; margin-right:8.95pt">Vital pregnancy rate</p></td><td style="height:25.8pt; vertical-align:top; width:58.8pt"><p style="margin-left:14.8pt; margin-right:0in">39.9%</p></td><td style="height:25.8pt; vertical-align:top; width:54.6pt"><p style="margin-left:12.75pt; margin-right:0in">39.1%</p></td><td style="height:25.8pt; vertical-align:top; width:74.75pt"><p style="margin-left:6.75pt; margin-right:0in">1.1 [-3.8, 5.9]</p></td><td style="height:25.8pt; vertical-align:top; width:61.45pt"><p style="margin-left:16.1pt; margin-right:0in">23.9%</p></td><td style="height:25.8pt; vertical-align:top; width:62.9pt"><p style="margin-left:16.85pt; margin-right:0in">26.9%</p></td><td style="height:25.8pt; vertical-align:top; width:71.9pt"><p style="margin-left:4.95pt; margin-right:0in">-3.0 [-7.3,</p><p style="margin-left:4.95pt">1.4]</p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:79.9pt"><p style="margin-left:5.1pt; margin-right:8.95pt">Ongoing pregnancy rate</p></td><td style="height:25.8pt; vertical-align:top; width:58.8pt"><p style="margin-left:14.8pt; margin-right:0in">39.0%</p></td><td style="height:25.8pt; vertical-align:top; width:54.6pt"><p style="margin-left:12.75pt; margin-right:0in">38.1%</p></td><td style="height:25.8pt; vertical-align:top; width:74.75pt"><p style="margin-left:6.75pt; margin-right:0in">1.1 [-3.8, 5.9]</p></td><td style="height:25.8pt; vertical-align:top; width:61.45pt"><p style="margin-left:16.1pt; margin-right:0in">22.2%</p></td><td style="height:25.8pt; vertical-align:top; width:62.9pt"><p style="margin-left:16.85pt; margin-right:0in">24.0%</p></td><td style="height:25.8pt; vertical-align:top; width:71.9pt"><p style="margin-left:4.95pt; margin-right:0in">-1.9 [-6.1,</p><p style="margin-left:4.95pt">2.3]</p></td></tr><tr><td style="border-color:black; height:25.9pt; vertical-align:top; width:79.9pt"><p style="margin-left:5.1pt; margin-right:0in">Live birth rate*</p></td><td style="height:25.9pt; vertical-align:top; width:58.8pt"><p style="margin-left:14.8pt; margin-right:0in">35.6%</p></td><td style="height:25.9pt; vertical-align:top; width:54.6pt"><p style="margin-left:12.75pt; margin-right:0in">34.4%</p></td><td style="height:25.9pt; vertical-align:top; width:74.75pt"><p style="margin-left:6.75pt; margin-right:0in">1.3 [-3.5, 6.1]</p></td><td style="height:25.9pt; vertical-align:top; width:61.45pt"><p style="margin-left:16.1pt; margin-right:0in">21.3%</p></td><td style="height:25.9pt; vertical-align:top; width:62.9pt"><p style="margin-left:16.85pt; margin-right:0in">23.4%</p></td><td style="height:25.9pt; vertical-align:top; width:71.9pt"><p style="margin-left:4.95pt; margin-right:0in">-2.3 [-6.5,</p><p style="margin-left:4.95pt">1.9]</p></td></tr></tbody></table><p style="margin-left:10.9pt">&dagger;</p><p style="margin-left:10.9pt; text-indent:3.2pt">The primary efficacy endpoint in the ENGAGE study was ongoing pregnancy (assessed at least 10 weeks after</p><p style="margin-left:10.9pt">embryo transfer).</p><p style="margin-left:10.9pt; margin-right:15.25pt">&Dagger;The primary efficacy endpoint in the PURSUE study was vital pregnancy rate defined as the percentage of subjects with at least one foetus with heart activity assessed 5 to 6 weeks after embryo transfer.</p><p style="margin-left:10.9pt">*Live birth rate was a secondary efficacy endpoint in ENGAGE and PURSUE.</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:15.25pt">In these clinical trials, the safety profile of a single injection with Elonva was comparable to daily injections with recFSH.</p><p>&nbsp;</p><p style="margin-left:10.9pt"><em>Pregnancy from the Frozen-Thawed Embryo Transfer (FTET)</em><em> </em><em>cycles of ENGAGE and PURSUE</em></p><p><em>&nbsp;</em></p><p style="margin-left:10.9pt; margin-right:15.25pt">The follow-up FTET trial for ENGAGE included women who had at least one embryo thawed for use up to at least one year after cryopreservation. The mean number of embryos transferred in the FTET cycles of ENGAGE was 1.7 in both treatment groups.</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:18.25pt">The follow-up FTET trial for PURSUE included women who had at least one embryo thawed for use within two years of the date of the last cryopreservation for this trial. The mean number of embryos transferred in the FTET cycles of PURSUE was 2.4 in both treatment groups. This trial also provided safety data on the infants born from cryopreserved embryos.</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:18.25pt">The maximum number of FTET cycles was 5 and 4 for the follow-up FTET trial for ENGAGE and PURSUE, respectively. The pregnancy results from the first two FTET cycles of ENGAGE and PURSUE are summarized in Table 3 below.</p><p>&nbsp;</p><p>Table 3: Pregnancy Results from the FTET cycles of ENGAGE and PURSUE Intent-to-Treat Population (ITT)</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:52.2pt; vertical-align:top; width:93.5pt"><p>&nbsp;</p></td><td style="border-color:black; height:52.2pt; vertical-align:top; width:174.5pt" colspan="6"><p style="margin-left:24.75pt; margin-right:24.65pt; text-align:center"><strong>FTET Cycles of ENGAGE</strong><strong> </strong><strong>(18</strong>-<strong>36</strong><strong> years of age)</strong></p><p style="margin-left:11.8pt; margin-right:11.85pt; text-align:center"><strong>(body weight greater than 60 kg</strong><strong> </strong><strong>and less than or equal to 90</strong><strong> kg)</strong></p></td><td style="border-color:black; height:52.2pt; vertical-align:top; width:196.3pt" colspan="6"><p style="margin-left:37.5pt; margin-right:37.35pt; text-align:center"><strong>FTET Cycles of PURSUE</strong><strong> </strong><strong>(35</strong>-<strong>42</strong><strong> years of age)</strong></p><p style="margin-left:10.0pt; margin-right:10.0pt; text-align:center"><strong>(body weight greater than or equal to</strong><strong> </strong><strong>50 kg)</strong></p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:93.5pt"><p>&nbsp;</p></td><td style="height:25.8pt; vertical-align:top; width:86.5pt" colspan="3"><p style="margin-left:27.3pt; margin-right:26.35pt; text-indent:-1.0pt"><strong>Elonva</strong><strong> </strong><strong>150 &micro;g</strong></p></td><td style="height:25.8pt; vertical-align:top; width:87.95pt" colspan="3"><p style="margin-left:27.9pt; margin-right:25.55pt; text-indent:-2.3pt"><strong>recFSH</strong><strong> </strong><strong>200 IU</strong></p></td><td style="height:25.8pt; vertical-align:top; width:98.75pt" colspan="3"><p style="margin-left:33.5pt; margin-right:32.35pt; text-indent:-1.0pt"><strong>Elonva</strong><strong> </strong><strong>150 &micro;g</strong></p></td><td style="height:25.8pt; vertical-align:top; width:97.55pt" colspan="3"><p style="margin-left:32.7pt; margin-right:30.35pt; text-indent:-2.3pt"><strong>recFSH</strong><strong> </strong><strong>300 IU</strong></p></td></tr><tr><td style="border-color:black; height:19.2pt; vertical-align:top; width:93.5pt"><p>&nbsp;</p></td><td style="height:19.2pt; vertical-align:top; width:29.15pt"><p style="text-align:center"><strong>n</strong></p></td><td style="height:19.2pt; vertical-align:top; width:27.25pt"><p style="margin-left:0in; margin-right:.05pt; text-align:center"><strong>N</strong></p></td><td style="height:19.2pt; vertical-align:top; width:30.1pt"><p style="margin-left:9.15pt; margin-right:0in"><strong>%</strong></p></td><td style="height:19.2pt; vertical-align:top; width:28.1pt"><p style="text-align:center"><strong>n</strong></p></td><td style="height:19.2pt; vertical-align:top; width:27.35pt"><p style="margin-left:.05pt; margin-right:0in; text-align:center"><strong>N</strong></p></td><td style="height:19.2pt; vertical-align:top; width:32.5pt"><p style="margin-left:10.35pt; margin-right:0in"><strong>%</strong></p></td><td style="height:19.2pt; vertical-align:top; width:32.9pt"><p style="text-align:center"><strong>n</strong></p></td><td style="height:19.2pt; vertical-align:top; width:33.0pt"><p style="margin-left:0in; margin-right:.05pt; text-align:center"><strong>N</strong></p></td><td style="height:19.2pt; vertical-align:top; width:32.9pt"><p style="margin-left:10.5pt; margin-right:0in"><strong>%</strong></p></td><td style="height:19.2pt; vertical-align:top; width:32.65pt"><p style="text-align:center"><strong>n</strong></p></td><td style="height:19.2pt; vertical-align:top; width:32.5pt"><p style="margin-left:0in; margin-right:.05pt; text-align:center"><strong>N</strong></p></td><td style="height:19.2pt; vertical-align:top; width:.45in"><p style="margin-left:10.35pt; margin-right:0in"><strong>%</strong></p></td></tr><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:93.5pt"><p style="margin-left:5.1pt"><strong>FTET</strong><strong> </strong><strong>Cycle 1</strong><strong>a</strong></p></td><td style="height:14.65pt; vertical-align:top; width:29.15pt"><p>&nbsp;</p></td><td style="height:14.65pt; vertical-align:top; width:27.25pt"><p>&nbsp;</p></td><td style="height:14.65pt; vertical-align:top; width:30.1pt"><p>&nbsp;</p></td><td style="height:14.65pt; vertical-align:top; width:28.1pt"><p>&nbsp;</p></td><td style="height:14.65pt; vertical-align:top; width:27.35pt"><p>&nbsp;</p></td><td style="height:14.65pt; vertical-align:top; width:32.5pt"><p>&nbsp;</p></td><td style="height:14.65pt; vertical-align:top; width:32.9pt"><p>&nbsp;</p></td><td style="height:14.65pt; vertical-align:top; width:33.0pt"><p>&nbsp;</p></td><td style="height:14.65pt; vertical-align:top; width:32.9pt"><p>&nbsp;</p></td><td style="height:14.65pt; vertical-align:top; width:32.65pt"><p>&nbsp;</p></td><td style="height:14.65pt; vertical-align:top; width:32.5pt"><p>&nbsp;</p></td><td style="height:14.65pt; vertical-align:top; width:.45in"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:27.25pt; vertical-align:top; width:93.5pt"><p style="margin-left:13.1pt; margin-right:33.65pt; text-indent:-5.3pt">Ongoing pregnancy</p></td><td style="height:27.25pt; vertical-align:top; width:29.15pt"><p style="margin-left:8.7pt; margin-right:0in">55</p></td><td style="height:27.25pt; vertical-align:top; width:27.25pt"><p style="margin-left:4.95pt; margin-right:0in">148</p></td><td style="height:27.25pt; vertical-align:top; width:30.1pt"><p style="margin-left:5.1pt; margin-right:0in">37.2</p></td><td style="height:27.25pt; vertical-align:top; width:28.1pt"><p style="margin-left:8.1pt; margin-right:0in">45</p></td><td style="height:27.25pt; vertical-align:top; width:27.35pt"><p style="margin-left:5.1pt; margin-right:0in">147</p></td><td style="height:27.25pt; vertical-align:top; width:32.5pt"><p style="margin-left:6.3pt; margin-right:0in">30.6</p></td><td style="height:27.25pt; vertical-align:top; width:32.9pt"><p style="margin-left:10.6pt; margin-right:0in">43</p></td><td style="height:27.25pt; vertical-align:top; width:33.0pt"><p style="margin-left:7.85pt; margin-right:0in">152</p></td><td style="height:27.25pt; vertical-align:top; width:32.9pt"><p style="margin-left:6.4pt; margin-right:0in">28.3</p></td><td style="height:27.25pt; vertical-align:top; width:32.65pt"><p style="margin-left:10.5pt; margin-right:0in">42</p></td><td style="height:27.25pt; vertical-align:top; width:32.5pt"><p style="margin-left:7.6pt; margin-right:0in">145</p></td><td style="height:27.25pt; vertical-align:top; width:.45in"><p style="margin-left:6.3pt; margin-right:0in">29.0</p></td></tr><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:93.5pt"><p style="margin-left:7.85pt; margin-right:0in">Live birth</p></td><td style="height:14.65pt; vertical-align:top; width:29.15pt"><p style="text-align:center">-</p></td><td style="height:14.65pt; vertical-align:top; width:27.25pt"><p style="margin-left:0in; margin-right:.15pt; text-align:center">-</p></td><td style="height:14.65pt; vertical-align:top; width:30.1pt"><p style="margin-left:0in; margin-right:.15pt; text-align:center">-</p></td><td style="height:14.65pt; vertical-align:top; width:28.1pt"><p style="margin-left:0in; margin-right:.05pt; text-align:center">-</p></td><td style="height:14.65pt; vertical-align:top; width:27.35pt"><p style="margin-left:0in; margin-right:.05pt; text-align:center">-</p></td><td style="height:14.65pt; vertical-align:top; width:32.5pt"><p style="margin-left:0in; margin-right:.15pt; text-align:center">-</p></td><td style="height:14.65pt; vertical-align:top; width:32.9pt"><p style="margin-left:10.6pt; margin-right:0in">43</p></td><td style="height:14.65pt; vertical-align:top; width:33.0pt"><p style="margin-left:7.85pt; margin-right:0in">152</p></td><td style="height:14.65pt; vertical-align:top; width:32.9pt"><p style="margin-left:6.4pt; margin-right:0in">28.3</p></td><td style="height:14.65pt; vertical-align:top; width:32.65pt"><p style="margin-left:10.5pt; margin-right:0in">41</p></td><td style="height:14.65pt; vertical-align:top; width:32.5pt"><p style="margin-left:7.6pt; margin-right:0in">145</p></td><td style="height:14.65pt; vertical-align:top; width:.45in"><p style="margin-left:6.3pt; margin-right:0in">28.3</p></td></tr><tr><td style="border-color:black; height:14.75pt; vertical-align:top; width:93.5pt"><p style="margin-left:5.1pt"><strong>FTET</strong><strong> </strong><strong>Cycle 2</strong><strong>a</strong></p></td><td style="height:14.75pt; vertical-align:top; width:29.15pt"><p>&nbsp;</p></td><td style="height:14.75pt; vertical-align:top; width:27.25pt"><p>&nbsp;</p></td><td style="height:14.75pt; vertical-align:top; width:30.1pt"><p>&nbsp;</p></td><td style="height:14.75pt; vertical-align:top; width:28.1pt"><p>&nbsp;</p></td><td style="height:14.75pt; vertical-align:top; width:27.35pt"><p>&nbsp;</p></td><td style="height:14.75pt; vertical-align:top; width:32.5pt"><p>&nbsp;</p></td><td style="height:14.75pt; vertical-align:top; width:32.9pt"><p>&nbsp;</p></td><td style="height:14.75pt; vertical-align:top; width:33.0pt"><p>&nbsp;</p></td><td style="height:14.75pt; vertical-align:top; width:32.9pt"><p>&nbsp;</p></td><td style="height:14.75pt; vertical-align:top; width:32.65pt"><p>&nbsp;</p></td><td style="height:14.75pt; vertical-align:top; width:32.5pt"><p>&nbsp;</p></td><td style="height:14.75pt; vertical-align:top; width:.45in"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:27.35pt; vertical-align:top; width:93.5pt"><p style="margin-left:13.1pt; margin-right:33.65pt; text-indent:-5.3pt">Ongoing pregnancy</p></td><td style="border-color:black; height:27.35pt; vertical-align:top; width:29.15pt"><p style="text-align:center">9</p></td><td style="border-color:black; height:27.35pt; vertical-align:top; width:27.25pt"><p style="margin-left:7.75pt; margin-right:0in">38</p></td><td style="border-color:black; height:27.35pt; vertical-align:top; width:30.1pt"><p style="margin-left:5.1pt; margin-right:0in">23.7</p></td><td style="border-color:black; height:27.35pt; vertical-align:top; width:28.1pt"><p style="margin-left:0in; margin-right:.1pt; text-align:center">9</p></td><td style="border-color:black; height:27.35pt; vertical-align:top; width:27.35pt"><p style="margin-left:7.85pt; margin-right:0in">31</p></td><td style="border-color:black; height:27.35pt; vertical-align:top; width:32.5pt"><p style="margin-left:6.3pt; margin-right:0in">29.0</p></td><td style="border-color:black; height:27.35pt; vertical-align:top; width:32.9pt"><p style="text-align:center">8</p></td><td style="border-color:black; height:27.35pt; vertical-align:top; width:33.0pt"><p style="margin-left:10.6pt; margin-right:0in">23</p></td><td style="border-color:black; height:27.35pt; vertical-align:top; width:32.9pt"><p style="margin-left:6.4pt; margin-right:0in">34.8</p></td><td style="border-color:black; height:27.35pt; vertical-align:top; width:32.65pt"><p style="text-align:center">6</p></td><td style="border-color:black; height:27.35pt; vertical-align:top; width:32.5pt"><p style="margin-left:10.35pt; margin-right:0in">14</p></td><td style="border-color:black; height:27.35pt; vertical-align:top; width:.45in"><p style="margin-left:6.3pt; margin-right:0in">42.9</p></td></tr><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:93.5pt"><p style="margin-left:7.85pt; margin-right:0in">Live birth</p></td><td style="height:14.65pt; vertical-align:top; width:29.15pt"><p style="text-align:center">-</p></td><td style="height:14.65pt; vertical-align:top; width:27.25pt"><p style="margin-left:0in; margin-right:.15pt; text-align:center">-</p></td><td style="height:14.65pt; vertical-align:top; width:30.1pt"><p style="margin-left:0in; margin-right:.15pt; text-align:center">-</p></td><td style="height:14.65pt; vertical-align:top; width:28.1pt"><p style="margin-left:0in; margin-right:.05pt; text-align:center">-</p></td><td style="height:14.65pt; vertical-align:top; width:27.35pt"><p style="margin-left:0in; margin-right:.05pt; text-align:center">-</p></td><td style="height:14.65pt; vertical-align:top; width:32.5pt"><p style="margin-left:0in; margin-right:.15pt; text-align:center">-</p></td><td style="height:14.65pt; vertical-align:top; width:32.9pt"><p style="text-align:center">8</p></td><td style="height:14.65pt; vertical-align:top; width:33.0pt"><p style="margin-left:10.6pt; margin-right:0in">23</p></td><td style="height:14.65pt; vertical-align:top; width:32.9pt"><p style="margin-left:6.4pt; margin-right:0in">34.8</p></td><td style="height:14.65pt; vertical-align:top; width:32.65pt"><p style="text-align:center">6</p></td><td style="height:14.65pt; vertical-align:top; width:32.5pt"><p style="margin-left:10.35pt; margin-right:0in">14</p></td><td style="height:14.65pt; vertical-align:top; width:.45in"><p style="margin-left:6.3pt; margin-right:0in">42.9</p></td></tr></tbody></table><p style="margin-left:10.9pt; margin-right:0in">n = number of subjects with the event; N = total number of subjects</p><p style="margin-left:10.9pt; margin-right:0in">a Per embryo transfer.</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:19.05pt"><em>Congenital malformations reported in</em><em> </em><em>infants born after </em><em>a frozen-thawed embryo transfer (FTET) cycle</em></p><p style="margin-left:10.9pt; margin-right:15.25pt">Following use of Elonva, 61 infants were born after an FTET cycle in the PURSUE study follow-up, and 607 infants were born after fresh ART cycles in the ENSURE, ENGAGE and PURSUE studies combined. The rates for congenital malformations (major and minor combined) reported for infants born after an FTET cycle in the PURSUE study follow-up (16.4%) were similar to those reported for infants born after fresh ART cycles in the ENSURE, ENGAGE and PURSUE studies combined (16.8%).</p><p>&nbsp;</p><p style="margin-left:10.9pt"><em>Immunogenicity</em></p><p style="margin-left:10.9pt; margin-right:22.35pt">Of the 2,511 women treated with Elonva who were evaluated for the formation of post-treatment antibodies, four (0.16%) had evidence of antibody formation, including three who had been exposed once to Elonva and one who had been exposed twice to Elonva. In each case, these antibodies were non-neutralizing and did not interfere with the response to stimulation or the normal physiologic responses of the Hypothalamic-Pituitary-Ovarian (HPO) axis. Two of these four women became pregnant during the same treatment cycle in which antibodies were detected, suggesting that the presence of non-neutralizing antibodies after stimulation with Elonva is not clinically relevant.</p><p>&nbsp;</p><p style="margin-left:10.9pt"><u>Paediatric population</u></p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:18.25pt">The European Medicines Agency has deferred the obligation to submit the results of studies with Elonva in one or more subsets of the paediatric population in hypogonadotrophic hypogonadism (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:10.9pt">Pharmacokinetic parameters of corifollitropin alfa were evaluated after subcutaneous administration in women undergoing a COS treatment cycle.</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:19.05pt">Due to the long elimination half-life, after administration of the recommended dose, serum concentrations of corifollitropin alfa are sufficient to sustain multiple follicular growth for an entire week. This justifies replacement of the first seven injections of daily (rec)FSH with a single subcutaneous injection of Elonva in COS for the development of multiple follicles and pregnancy in an ART program (see section 4.2).</p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:13.1pt">Body weight is a determinant of exposure to corifollitropin alfa. Corifollitropin alfa exposure after a single subcutaneous injection is 665 hours*ng/mL (AUC, 426-1,037 hours*ng/mL1) and is similar after administration of 100 micrograms corifollitropin alfa to women with a body weight less than or &nbsp;&nbsp;&nbsp;&nbsp;equal to 60 kilograms and of 150 micrograms corifollitropin alfa to women with a body weight greater than 60 kilograms.</p><p>&nbsp;</p><p style="margin-left:10.9pt"><u>Absorption</u></p><p>&nbsp;</p><p style="margin-left:10.9pt; margin-right:19.45pt; text-align:justify">After a single subcutaneous injection of Elonva, the maximum serum concentration of corifollitropin alfa is 4.24 ng/mL (2.49-7.21 ng/mL1) and is reached 44 hours (35-57 hours1) postdose. The absolute bioavailability is 58% (48-70%1).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:10.55pt"><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1026" style='width:144.7pt;
 height:.7pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="2894,14">
 <v:group id="_x0000_s1027" style='position:absolute;left:7;top:7;width:2880;
  height:2' coordorigin="7,7" coordsize="2880,2">
  <v:shape id="_x0000_s1028" style='position:absolute;left:7;top:7;width:2880;
   height:2' coordorigin="7,7" coordsize="2880,0" path="m7,7r2880,e" filled="f"
   strokeweight=".7pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if !vml]--><img width="193" height="2" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/02/clip_image001.gif" /><!--[endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:144.7pt;
 height:.7pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p style="margin-left:10.9pt; margin-right:0in">1 Predicted range for 90% of subjects.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:18.85pt">Distribution, metabolism and elimination of corifollitropin alfa are very similar to other gonadotropins, such as FSH, hCG and LH. After absorption into the blood, corifollitropin alfa is distributed mainly to the ovaries and the kidneys. The steady state volume of distribution is 9.2 L (6.5-13.1 L1). Exposure to corifollitropin alfa increases proportionally with dose within the range of 60 micrograms to 240 micrograms.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p style="margin-right:9.4pt">Corifollitropin alfa has an elimination half-life of 70 hours (59-82 hours1) and a clearance of 0.13 L/h (0.10-0.18 L/h1). Elimination of corifollitropin alfa predominantly occurs via the kidneys, and the rate of elimination may be reduced in patients with renal insufficiency (see sections 4.2 and 4.4). Hepatic metabolism contributes to a minor extent to the elimination of corifollitropin alfa.</p><p>&nbsp;</p><p><u>Other special populations</u></p><p>&nbsp;</p><p style="margin-left:5.9pt; margin-right:0in"><em>Hepatic impairment</em></p><p style="margin-left:5.9pt; margin-right:12.05pt">Although data in hepatically impaired patients are not available, hepatic impairment is unlikely to affect the pharmacokinetic profile of corifollitropin alfa.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p style="margin-right:17.8pt">Preclinical data revealed no special hazard for humans based on conventional studies of single and repeated dose toxicity and safety pharmacology.</p><p>&nbsp;</p><p style="margin-right:11.4pt">Reproduction toxicology studies in rats and rabbits indicated that corifollitropin alfa does not adversely affect fertility. Administration of corifollitropin alfa to rats and rabbits, prior to and directly after mating, and during early pregnancy, resulted in embryotoxicity. In rabbits, when administered prior to mating, teratogenicity has been observed. Both embryotoxicity and teratogenicity are considered a consequence of the superovulatory state of the animal not able to support a number of</p><p>embryos above a physiological ceiling. The relevance of these findings for the clinical use of Elonva is limited.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:11.4pt">Sodium citrate dihydrate (3.68 mg)</p><p style="margin-right:11.4pt">Sucrose (35 mg)</p><p style="margin-right:11.4pt">Polysorbate 20 (0.10 mg)</p><p style="margin-right:11.4pt">L-Methionine (0.25 mg)</p><p style="margin-right:11.4pt">Sodium hydroxide (for pH adjustment) (q.s. to pH 7)</p><p style="margin-right:11.4pt">Hydrochloric acid (for pH adjustment) (q.s. to pH 7)</p><p style="margin-right:11.4pt">Water for injections (q.s. to 0.50 ml)</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p style="margin-right:11.4pt">&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, the medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:297.0pt">Store in a refrigerator (2&deg;C-8&deg;C). Do not freeze.</p><p>For convenience, the patient is allowed to store the product at or below 30&deg;C for a period of not more than 1 month.</p><p>&nbsp;</p><p>Keep the syringe in the outer carton in order to protect from light.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:6.55pt">Elonva is supplied in pre-filled luerlock syringes of 1 mL (type I hydrolytic glass), closed with a bromobutyl elastomer plunger and a tip cap. The syringe is equipped with an automatic safety system to prevent needle stick injuries after use and is packed together with a sterile injection needle. Each pre-filled syringe contains 0.5 mL solution for injection.</p><p>&nbsp;</p><p>Elonva is available in pack sizes of 1 pre-filled syringe.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not use Elonva if the solution is not clear.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Merck Sharp & Dohme Limited Hertford Road
Hoddesdon
Hertfordshire EN11 9BU United Kingdom

Manufacturer:
Vetter Pharma- Fertigung GmbH & Co. KG, Schützenstrasse 87 and 99-101, 88212 Ravensburg, Germany.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>